UNeMed Technology Portfolio

TECHNOLOGY1
2020
University of Nebraska
TECHNOLOGY PORTFOLIO
cancer PORTFOLIO
cardiovascular
drug delivery
infectious diseases
medical devices
metabolic
miscellaneous
neurologic
research tools
software
startups
Revised: October 1, 2020

TECHNOLOGY
2020
PORTFOLIO
facebook.com/unemedcorp
twitter.com/unemed
bit.ly/UNeMedVideo
bit.ly/UNePics
bit.ly/UNeMedLink
402-559-2468
unemed@unmc.edu
http://www.unemed.com
Mail:
986099 Nebraska Medical Center
Omaha, Nebraska 68198-6099
Location:
4460 Farnam St., Ste. 3000
TECHNOLOGY
2020
Contents PORTFOLIO
cancer........................... 2
cardiovascular........... 12
drug delivery.............. 16
infectious diseases.... 22
medical devices......... 42
metabolic................... 78
miscellaneous............ 81
neurologic.................. 91
research tools............ 94
software................... 111
startups.................... 121
TECHNOLOGY
2020
cancer PORTFOLIO
cardiovascular
drug delivery
infectious diseases
medical devices
metabolic
miscellaneous
neurologic
research tools
software
startups
TECHNOLOGY
3
2020
University of Nebraska Medical Center
PORTFOLIO CANCER
Cancer classification algorithm
Identify critical cancer
biomarkers with a single sample
A new and powerful algorithm could help
in the diagnosis and prognosis of any Powerful prognosis,
cancer.
diagnosis tool
The discovery of cancer-specific gene n Reference based meth-
od for gene biomarker
biomarkers can significantly improve
discovery
diagnosis and enable personalized n Classify cancer type
Cancer
therapy. Unlike current cancer screening using gene expression
strategies that are largely based on data
imaging techniques, this algorithm n Diagnosis, prognosis
represents a purely data-driven method from a single clinical
to identify biomarkers. sample
n Novel algorithm re-
Unlike other gene discovery algorithms quires no prior knowl-
under development, this technology edge to use
requires relatively less processing
INVENTORS
power, yet provides true single-sample n Amar Singh, Ph.D.
diagnostic potential. Plus, the novel n Dhundy Bastola, Ph.D.
software is easy to use, and does not n Ling Zhang, Ph.D.
require medical knowledge for the user.
As a proof-of-concept, the inventors have used the algorithm to

positively identify specific biomarkers in colorectal, stomach and lung
cancer samples. However, the algorithm could be further trained to
theoretically identify biomarkers for many different diseases.
Contact:
Tyler Scherr
tyler.scherr@unmc.edu
402-559-2140
UNeMed Corporation is the technology transfer office for the University of
Nebraska Medical Center and the University of Nebraska at Omaha, serving 986099 Nebraska Medical Center
researchers, faculty and staff who develop new technologies and inventions. Omaha, NE 68198-6099
UNeMed strives to help bring those innovations to the marketplace. www.unemed.com
4 TECHNOLOGY
2020
University of Nebraska at Omaha
CANCER PORTFOLIO
SMZL specific biomarkers

Diagnose, monitor rare
lymphoma with blood sample
A new set of biomarkers
could help in the
diagnosis and prognosis
of a rare form of cancer.
Splenic marginal zone

lymphoma, a cancer
Cancer
of the spleen, affects

approximately 2,000
people annually in the
United States. However,
current diagnosis is
often times unclear and
typically requires removal
of part or all of the
spleen.
By systematically
analyzing 39,000
genes present in 437 clinical samples across 13 clinical datasets,
researchers at the University of Nebraska at Omaha identified a
unique 135-gene profile unique to
Track in real time this rare form of splenic lymphoma.
n Novel biomarkers for Intriguingly, separate subsets of seven
splenic marginal zone and two biomarkers were demonstrated
lymphoma to be greater than 93 percent accurate at
n Positively diagnose diagnosing splenic lymphoma versus all
SMZL from all other other B-cell lymphomas.
B-cell lymphomas
n Measure biomarkers Unlike most diagnostics, these
in blood and in fresh
biomarkers can be measured in blood as
or preserved splenic
biopsies well as fresh or preserved tissue samples.
n Potential to monitor
SMZL progression in With further validation, these biomarkers
real-time could also be used to monitor splenic
lymphoma progression and metastasis in
INVENTORS real-time, enabling oncologists to provide
n Christine Cutucache, timely and effective treatment.
Ph.D.
n Jacob Robinson, Ph.D.
Contact:
Tyler Scherr
402-559-2140

986099 Nebraska Medical Center Nebraska Medical Center and the University of Nebraska at Omaha, serving
Omaha, NE 68198-6099 researchers, faculty and staff who develop new technologies and inventions.
www.unemed.com UNeMed strives to help bring those innovations to the marketplace.
TECHNOLOGY
5
2020
PORTFOLIO CANCER
Microtubule targeting
New compounds allow
imaging, treatment of cancer
UNMC researchers have developed New Compounds to
compounds that are capable of not only
imaging and monitoring tumors, but treat, image cancer
treating them as well. n Microtubule-targeted
radiopharmaceuticals
n Images and treats
The new compounds specifically bind
cancer
Cancer
to protein-based structures called n Non-radioactive forms
microtubules. Microtubules play a critical of the drugs can
role in a number of cellular functions, induce cell death
and are a key target for treating a variety n Can be labeled with a
of cancers. variety of radionuclides
UNMC’s compounds selectively target INVENTORS

microtubules. The compounds can be n Janina Baranowska-
safely labeled with various radioactive Kortylewicz, Ph.D.
n Zbigniew Kortylewicz,
atoms that allow the compounds to
Ph.D.
be used for imaging (SPECT or PET)
and therapy. When used without the
radioactive isotopes, the
compounds can help kill
cancer cells and make
them more susceptible to
radiation therapy.
Microtubule-targeted
compounds labeled with
iodine-131 were tested
in a mouse model of
glioblastoma. Treatment
with the compound
significantly reduced tumor
size and weight. Additional
studies will look at the use
of other radionuclides such
as astatine-211.
Contact:
Matt Boehm
mboehm@unmc.edu
402-559-2166

6 TECHNOLOGY
2020
CANCER PORTFOLIO
New approach for myeloma, other cancers

Small molecule inhibitors
of GGDPS provide new
treatment approach for cancer
Researchers at the
Medical Center and the
University of Iowa have
Cancer
teamed up to develop
new drugs to help treat
multiple myeloma and
other types of cancer.
The new drugs

target a protein
called geranylgeranyl
diphosphate synthase,
also known as GGDPS.
GGDPS is involved in
the regulation of the
Rab family of small but important proteins that are also often linked to
cancer: GTPases. Targeting GGDPS may provide a way to inhibit Rab
family proteins, providing a
GGDPS Inhibitors unique way to treat various
forms of cancer.
n Small molecule inhibitors of GGDPS
n Nanomolar potency
n Novel treatment approach for multiple
The new GGDPS inhibitors
myeloma and other cancers have nanomolar potency
and are being assessed
INVENTORS in vivo to determine
n David Weimer, Ph.D. pharmacokinetics
n Sarah Holstein, Ph.D. properties and efficacy.
Contact:
Matt Boehm
mboehm@unmc.edu
402-559-2166

TECHNOLOGY
7
2020
PORTFOLIO CANCER
NF-κB Pathway Inhibitor

UNMC scientists invent new
compounds to treat cancer
Researchers at the
Medical Center created
a molecule capable of
specifically inhibiting
the NF-κB pathway, a
Cancer
key target involved in a
variety of cancers and
other diseases.
The NF-κB pathway

is often overactive in
a number of cancers.
Therefore, new ways to
shut off this pathway
could yield important
new cancer treatments.
Amarnath Natarajan, Ph.D., and his team developed a small molecule

called 36-252 that destroys key members of the NF-κB pathway—
specifically the proteins IKKβ and IKKα. In ovarian cancer cell studies,
36-252 effectively inhibited cell growth at nanomolar concentrations,
stimulated cell death (apoptosis), and effectively inhibited NF-κB
activity. 36-252 was also effective at destroying ovarian cancer stem-
like cells.
UNeMed is interested in
New Compounds to treat cancer forming collaborations with
n Inhibits the NF-κB pathway industry to further explore
n Causes degradation of IKKβ and IKKα the potential of 36-252
n Nanomolar potency in cell-based as a novel therapy of the
studies treatment of cancer and
other diseases associated
INVENTORS
n Amarnath Natarajan, Ph.D. with overactive NF-κB.
n Sandeep Rana, Ph.D.
Contact:
Matt Boehm
mboehm@unmc.edu
402-559-2166

8 TECHNOLOGY
2020
CANCER PORTFOLIO
Target for cancer stem cells

New drug target kills resistant
tumors in the deadliest cancers
Cancer drugs are only as good as their ability to kill the toughest cell
in a tumor, which is always the stem cell.
Stem cells—the cell-building dynamos that produce functional

organs and tissues—can sometimes have a dark side, exhibiting
cancerous properties. Known as cancer stem cells, they help
tumors resist and recover from treatment, and drivea cancer’s
Cancer
aggressiveness and ability to spread to other organs.
Some types of cancer, such as

pancreatic and ovarian cancer, are Unlock pancreatic cancer
particularly hardy thanks in large
n Proprietary, novel cancer
part to a robust population of these stem cell marker
cancer stem cells. In order for n siRNA knockdown induces
cancer treatment to be effective it susceptibility to gemcitabine
must target the cancer stem cell n Currently identifying small
population. molecule inhibitors of PD2
Researchers at the University of INVENTOR

Nebraska Medical Center, led by n Surinder Batra, Ph.D.
Surinder Batra, Ph.D., have found
that cancer stem cells have a
protein called PD2, or Pancreatic Differentiation Factor 2.
PD2 is normally involved in the maintenance of stem cells and

gives cancer stem cells the ability to replicate and develop drug
resistance. PD2 appears to be expressed along with other cancer
stem cell markers (CD133 and CD44) and self-renewal markers (Shh
and Oct3/4).
Dr. Batra’s research shows that shutting down PD2 could make
once-resistant cells vulnerable to cancer drugs. When PD2 was
inhibited, drug-resistant cells became susceptible to treatment with
the chemotherapy drug Gemcitabine. The results suggest PD2 may
be a compelling target for more effective cancer treatment.
UNMC researchers are currently screening libraries of small

molecules to identify potential inhibitors of PD2. Some candidates
have been identified and lead development is underway.
Contact:
Joe Runge
hrunge@unmc.edu
402-559-1181
TECHNOLOGY
9
2020
PORTFOLIO CANCER
CCL21-based immunotherapy for cancer
Use the immune system to
infiltrate and destroy tumors
University of Nebraska Medical Center researchers have found a way
to harness the power of the immune system to recruit immune cells to
help treat cancer.
Tatiana Bronich, Ph.D., and Joyce Solheim, Ph.D., have shown that
a protein messenger, or chemokine, called CCL21 can be used to
treat tumors. CCL21 is capable of attracting immune cells to the area
Cancer
where it’s administered.
However, one problem with this approach is that CCL21 doesn’t last
long inside the body, and therefore the effects of CCL21 are relatively
short-lived.
Personal option for
To get around this hurdle, Drs. Bronich cancer treatments
and Solheim created a new way to
deliver CCL21 directly to the tumor site n Personalized immuno-
while protecting it from degradation. The therapy
nanoformulation allows for extended n Extended release formu-
release of CCL21 within the tumor site, lation
which prolongs its effect and increases n Enhance existing immu-
the overall therapeutic impact. notherapies
INVENTORS
The CCL21 nanoparticle formulations
n Tatiana Bronich, Ph.D.
have been developed, and release n Joyce Solheim, Ph.D.
kinetics have been optimized.
Researchers have also performed small-
scale animal studies using subcutaneous Panc02 tumors where the
nanoformulated CCL21 showed significant inhibition of tumor growth
over nine days.
In addition to use as a standalone immunotherapy, the CCL21

nanoparticles can also enhance other immunotherapies.
By enhancing immune infiltration into tumors, the CCL21

nanoparticles can greatly enhance the efficacy of tumor vaccines, cell
therapies, oncolytic viruses, and antibody therapies. Future studies
will look at the benefits of co-administering CCL21 nanoparticles with
existing cancer immunotherapies.
Contact:
Matt Boehm
mboehm@unmc.edu
402-559-2166
10 TECHNOLOGY
2020
CANCER PORTFOLIO
NF-kB Pathway Inhibitors

Wage war against pancreatic
cancer with minimal side effects
There may finally be an answer to
pancreatic cancer.
Every year, roughly 45,000 people

are diagnosed with pancreatic
cancer, the most lethal form of
cancerous disease. With current
Cancer
treatment options, almost 43,000

of them will die within five years of
diagnosis.
The few treatments that exist are

too soon rendered impotent as
patients quickly develop resistance
to the drugs.
But researchers at the University of Nebraska Medical Center may

be able to increase the odds for those who receive the grim news.
Researchers at UNMC are working on a novel drug called “13-197”
that has shown promise in mouse models with relatively few side
effects.
“13-197” is still in preclinical development for pancreatic cancer,

and may be useful
Novel Inhibitors of the NF-kB Pathway in the treatment
n Novel drug of other forms of
n Orally Available cancer and other
n Few side effects diseases such as
n Potent inhibitor of cancer cell proliferation diabetes.
n Effective in pancreatic cancer animal model
n Treat other forms of cancer UNMC is interested
n Treat diabetes, other diseases in partnering with
INVENTORS
a pharmaceutical
n Amarnath Natarajan, Ph.D. company to further
n Qian Chen, Ph.D. develop “13-197”
n Vashti Bryant, Ph.D. and future analogs
n Rajkumar Rajule for clinical use.
Contact:
Matt Boehm
mboehm@unmc.edu
402-559-2166
TECHNOLOGY
11
2020
PORTFOLIO CANCER
Nanogel cancer treatment
Nanogel delivers cancer
treatment with fewer side effects
A new nanogel under
development at the
Medical Center may
dramatically reduce the
multitude of adverse
side effects often
Cancer
associated with modern
cancer treatments.
Most cancer treatments

require a strategy
that incorporates
a combination of
therapies, which can
be detrimental to the patient’s health. Until now there haven’t been
many effective ways to specifically target cancerous cells.
A nanogel developed by former UNMC researcher Alexander

Kabanov, M.D., makes possible a simultaneous delivery of multiple
drugs to specific cancer sites.
By “tagging” the nanogel with
Target cancer sites a tumor-recognizing antibody,
physicians gain the ability to target
n Novel nanogel formulation cancer sites with smaller effective
n Allows for targeted delivery doses and a significant reduction in
of multiple drugs potential side effects.
n Allows for a lowered effec-
tive dose Proof of principle studies show
n Minimizes side effects the nanogel can effectively deliver
n Targets cancer cells multiple chemotherapy drugs,
and can also be used with a wide
INVENTORS
n Tatiana Bronich, Ph.D.
range of drugs and drug classes,
n Alexander Kabanov, Ph.D. including peptides, proteins and
gene therapy agents.
Contact:
Matt Boehm
mboehm@unmc.edu
402-559-2166
TECHNOLOGY
2020
cancer PORTFOLIO
cardiovascular
drug delivery
infectious diseases
medical devices
metabolic
miscellaneous
neurologic
research tools
software
startups
TECHNOLOGY
13
2020
PORTFOLIO CARDIOVASCULAR
Sympathetic vasomotion monitoring
New device will improve outcomes
Cardiovascular
in renal denervation procedures
Researchers at UNMC developed a
device capable of making high blood Rundown
n Detects small changes
pressure more treatable by accurately
n Measures success of
measuring the rhythmic constriction renal denervation
and relaxation of blood vessels, known n Increase success rate
as sympathetic vasomotion. n Can screen for blood
pressure-related fainting
The sympathetic nervous system n non-invasive
controls the body’s automated hemodynamic
functions such as digestion, heart rate monitoring
and the vasomotion of blood vessels.
Disruption of the sympathetic nervous INVENTORS
n Irving Zucker, Ph.D.
system can contribute to a variety of
n Alicia Schiller
chronic diseases, including high blood n Peter Pellegrino
pressure.
One potentially effective way to treat high blood pressure is to

destroy, or ablate, all or parts of the sympathetic nerves of the
kidneys. The problem, however, is until now there has not been
an accurate tool that helps clinicians in real-time determine if the
procedure is targeting the proper areas of the kidneys.
UNMC’s detection system non-invasively monitors sympathetic

nerve activity in real time and determines if a renal denervation
procedure was successful. This technology will help significantly
increase the success rate of renal denervation procedures.
UNMC researchers have shown that the sympathetic vasomotion

detection system can accurately detect renal denervation in rat
and rabbit models. A current study in pigs is expected to further
validate the system’s ability and accuracy.
The sympathetic vasomotion detection system is a versatile tool

that can also monitor and detect other diseases or conditions
associated with the sympathetic nervous system.
In addition to their work with renal denervation, UNMC researchers

are also investigating the device’s use as a screening tool for
blood pressure-related fainting and non-invasive hemodynamic
monitoring.
Contact:
Matt Boehm
mboehm@unmc.edu
402-559-2166
14 TECHNOLOGY
2020
CARDIOVASCULAR PORTFOLIO
Rapid co-culture model for atherosclerotic diseases

New way finds better
Cardiovascular
drugs for heart disease
A team of scientists
at UNMC invented a
milestone between the
petri dish and animal
tests, which could save
the drug development
industry untold millions
in research and
development. Using
a known technique
called co-culture, the
scientists invented a
highly efficient way to
create artificial arteries
that could reduce the Gap junction between the endothelial cells (arrow heads)
cost of drug discovery. were identified under scanning electron microscope.
Monocytes bond to endothelial cells at gap junction area
(white arrows). Monocyte migrated into and underneath the
In the complex and endothelial cell layer (red arrow).
expensive realm of
drug discovery, scientists screen drugs
in a series of increasingly expensive Better drugs for
experiments. One of the earliest jumps in heart disease
expense is going from testing drugs on n Low cost, easy to
cells in a petri dish to testing the drugs in produce co-culture
living animals. Frequently, drugs that work model
in the petri dish eventually fail in animals. n Accurately models
artery physiology
But now, UNMC’s inventors can create n Inexpensively simu-
a simulated artery that models the lates atherosclerotic
disease
progression of coronary artery disease.
The model can test new drugs that slow INVENTORS
or reverse the progression of the leading n Ioannis Chatzizisis,
cause of death in the United States, M.D., Ph.D.
coronary artery disease. n Xiang-De Liu, M.D.
Contact:
Joe Runge
hrunge@unmc.edu
402-559-1181

TECHNOLOGY
15
2020
PORTFOLIO CARDIOVASCULAR
Cardiac vascular access graft
Better care for children with heart defects
Cardiovascular
Many babies born with congenital defects of the heart now live to
become adults. Pediatric congenital heart disease and the heart
defects that it produces used to be completely lethal. Surgery for
congenital heart defects can now correct the majority of these
heart defects in infants.
Treatment of heart
defects in infants Managing congenital heart disease
n No deviation from current correction of
came from tireless congenital heart defects
innovation for congenital n Improved access for better manage-
heart defect surgery ment
and the combined n Easier to use, more efficient
expertise of teams
of medical experts. INVENTOR
Pediatric cardiologist n Jeff Delaney, M.D.
Jeffrey Delaney MD
and pediatric thoracic
surgeon James Hammel MD embody that innovation.
Dr. Hammel surgically corrects birth defects of the heart and Dr.
Delaney manages children living with congenital defects of the
heart. Their collaboration is the kind of care that has produced the
first generation of adults with congenital heart disease.
Together, they have invented a new pediatric medical device to

correct heart defects. The device, utilized in the final stages of a
Fontan procedure, will help facilitate management of the patient’s
congenital heart defects. A novel shunt, the device replaces
traditional tubes that redirect blood flow away from defective parts
of the hearth.
The improved device has permeable membranes to help the

cardiologist regulate pressure in the tube. A radio opaque
ring wreaths the membrane, making it easy to locate utilizing
radiography.
Doctors Hammel and Delaney are prepared to conduct an animal

study that will further validate the device. Contact UNeMed to
discuss how to bring this vital new device to market and give
children with life threatening heart defects more options in their
care.
Contact:
Matt Boehm
mboehm@unmc.edu
402-559-2166
TECHNOLOGY
2020
cancer PORTFOLIO
cardiovascular
drug delivery
infectious diseases
medical devices
metabolic
miscellaneous
neurologic
research tools
software
startups
TECHNOLOGY
17
2020
PORTFOLIO DRUG DELIVERY
CCL21-based immunotherapy
Use the immune system to
infiltrate and destroy tumors
Drug Delivery
University of Nebraska Medical Center researchers have found a way
to harness the power of the immune system to recruit immune cells
to help treat cancer.
Tatiana Bronich, Ph.D., and Joyce Solheim, Ph.D., have shown that
a protein messenger, or chemokine, called CCL21 can be used to
treat tumors. CCL21 is capable of attracting immune cells to the area
where it’s administered.
However, one problem with this approach is that CCL21 doesn’t last
long inside the body, and therefore the effects of CCL21 are relatively
short-lived.
To get around this hurdle, Drs.

Bronich and Solheim created Rundown
a new way to deliver CCL21 n Personalized immunotherapy
directly to the tumor site while n Extended release formulation
protecting it from degradation. n Enhance existing immunotherapies
The nanoformulation allows INVENTORS
for extended release of n Tatiana Bronich, Ph.D.
CCL21 within the tumor site, n Joyce Solheim, Ph.D.
which prolongs its effect
and increases the overall
therapeutic impact.
The CCL21 nanoparticle formulations have been developed, and

release kinetics have been optimized. Researchers have also
performed small-scale animal studies using subcutaneous Panc02
tumors where the nanoformulated CCL21 showed significant
inhibition of tumor growth over nine days.
In addition to use as a standalone immunotherapy, the CCL21

nanoparticles can also enhance other immunotherapies.
By enhancing immune infiltration into tumors, the CCL21

nanoparticles can greatly enhance the efficacy of tumor vaccines, cell
therapies, oncolytic viruses, and antibody therapies. Future studies
will look at the benefits of co-administering CCL21 nanoparticles with
existing cancer immunotherapies.
Contact:
Matt Boehm
mboehm@unmc.edu
402-559-2166
18 TECHNOLOGY
2020
DRUG DELIVERY PORTFOLIO
Anti-inflammatory polymers for IBD

New polymer system directly targets
inflammation in digestive system
Drug Delivery
Researchers at the University of Nebraska have found a way to
improve the treatment of inflammatory bowel diseases, Crohn’s
disease and ulcerative colitis.
The new therapy is based on an improved version of chloroquine, a

traditional malaria treatment with potent anti-inflammatory properties.
Taking chloroquine systemically for long periods of time can cause
negative side effects, including irreversible retina damage and hearing
loss. But UNMC’s new chloroquine-based polymers directly target
inflammation within the digestive system, harnessing chloroquine’s
anti-inflammatory effects while minimizing side effects.
The digestive system does not actively absorb the chloroquine-

based polymers because they are so large. Instead, the polymers are
localized within the digestive tract where they can have a direct effect
and maximum impact on inflammatory bowel disease.
The chloroquine-based polymers can also be used to package and

deliver other drugs to help treat inflammatory bowel disease.
Initial animal
studies have Anti-inflammatory polymers for IBD
been conducted
demonstrating n Orally administered therapy for IBD
localization of n Targeted to the digestive system
orally administered n Decreased dosing for ART therapy
chloroquine-based n Capable of packaging and delivering
polymers to the additional drugs
digestive tract.
INVENTORS
n David Oupicky, M.D.
n Fei Yu, Ph.D.
Contact:
Matt Boehm
mboehm@unmc.edu
402-559-2166
TECHNOLOGY
19
2020
Long-acting antiretroviral therapy
New delivery method opens
powerful option for HIV treatment
Drug Delivery
Researchers at the University of Nebraska Medical Center have
discovered a way to revolutionize the treatment of HIV. Early studies
show UNMC’s novel approach could reduce the regimen to a single
treatment once every month, eliminating the need for current strategies
that require daily administration of medicine.
Antiretroviral therapies, or ART, are also ineffective at reaching viral

reservoirs such as the lymph nodes and the central nervous system.
These viral reservoirs
essentially serve as a
bunkers that shelter
HIV from current
Nano-formulated antiretroviral
medications. But UNMC therapy for the treatment of HIV
researchers overcame
this obstacle with a new n Sustained delivery of antiretroviral drugs
nanoformulation called n Increased penetration into viral reservoirs
n Decreased dosing for ART therapy
LaserART.
n Less frequent dosing for ART therapy
LaserART harnesses the INVENTORS
power of the patient’s n Howard Gendelman, M.D.
immune system to n Alexander V. Kabanov, Ph.D.
store and deliver ART n Xinming Liu, Ph.D.
medications throughout
the entire body in a
sustained release
formulation.
LaserART targets the immune system’s hunter cells, or macrophages,

which roam the body on a perpetual seek and destroy mission looking
for foreign invaders. LaserART piggybacks on the macrophages, which
have full access to all parts of the body, including the central nervous
system—a particularly difficult system to hack for most modern
medicines.
Early tests on mouse models and large animals show that LaserART
produces a sustained release with long-lasting antiretroviral activity.
With further development LaserART could have a dramatic impact on

the estimated 34.2 million people on the planet who are affected by
HIV. The Centers for Disease Control estimates 1.1 million Americans
are living with HIV infection.
Contact:
Matt Boehm
mboehm@unmc.edu
402-559-2166

20 TECHNOLOGY
2020
DRUG DELIVERY PORTFOLIO
Nanofiber rings
Implant, customize drug delivery device
Researchers at the University
Drug Delivery
of Nebraska Medical
Center have developed
a new implantable drug
delivery device made out of
nanofibers.
This new device is a

nanofiber-based ring that is
biodegradable, versatile and
customizable.
The nanofiber rings can

be loaded with a variety
of different types of drugs
including small molecules
and biologics. The devices can
also be loaded with multiple
drugs at one time, allowing for Rundown
the delivery of a combination n Capable of delivering, variety of
therapy. drugs, including small molecules
and biologics
Another unique property of this n Biodegradable
device is that the nanofiber n Can be loaded with more than
rings can be customized to one drug at a time
n Release kinetics of each drug
allow for different release
can be tailored
properties of each drug loaded
into the ring. This includes INVENTOR
delayed release of drugs, n Jingwei Xie, Ph.D.
sequential release of multiple
drugs, and parallel release of
multiple drugs.
The unique properties of the nanofiber ring structure make it ideal

for use as an implantable drug delivery device.
Contact:
Matt Boehm
mboehm@unmc.edu
402-559-2166
TECHNOLOGY
21
2020
Nanogel cancer treatment
Nanogel delivers cancer
treatment with fewer side effects
Drug Delivery
A new nanogel
under development
at the University
of Nebraska
Medical Center may
dramatically reduce
the multitude of
adverse side effects
often associated
with modern cancer
treatments.
Most cancer
treatments require a
strategy that incorporates a combination of therapies, which can
be detrimental to the patient’s health. Until now there haven’t been
many effective ways to specifically target cancerous cells.
A nanogel developed by former UNMC researcher Alexander

Kabanov, M.D., makes possible a simultaneous delivery of multiple
drugs to specific cancer sites. By “tagging” the nanogel with a
tumor-recognizing antibody, physicians gain the ability to target
cancer sites with smaller effective doses and a significant reduction
in potential side effects.
Proof of principle
studies show
Target cancer sites the nanogel
can effectively
n Novel nanogel formulation deliver multiple
n Allows for targeted delivery of multiple drugs chemotherapy
n Allows for a lowered effective dose
n Minimizes side effects
drugs, and can
n Targets cancer cells also be used with
a wide range of
INVENTORS drugs and drug
n Tatiana Bronich, Ph.D. classes, including
n Alexander Kabanov, Ph.D. peptides, proteins
and gene therapy
agents.
Contact:
Matt Boehm
mboehm@unmc.edu
402-559-2166
TECHNOLOGY
2020
cancer PORTFOLIO
cardiovascular
drug delivery
infectious diseases
medical devices
metabolic
miscellaneous
neurologic
research tools
software
startups
Photo: National Institute of Allergy and Infectious Diseases

TECHNOLOGY
23
2020
PORTFOLIO INFECTIOUS DISEASES
Long-acting antiretroviral therapy
New delivery method opens
Infectious Diseases
powerful option for HIV treatment
discovered a way to revolutionize the treatment of HIV. Early studies
show UNMC’s novel approach could reduce the regimen to a single
treatment once every month, eliminating the need for current strategies
that require daily administration of medicine.
Antiretroviral therapies,
or ART, are also Nano-formulated antiretroviral
ineffective at reaching
viral reservoirs such as therapy for the treatment of HIV
the lymph nodes and
n Sustained delivery of antiretroviral drugs
the central nervous
n Increased penetration into viral reservoirs
system. These viral n Decreased dosing for ART therapy
reservoirs essentially n Less frequent dosing for ART therapy
serve as a bunkers that
shelter HIV from current INVENTORS
medications. But UNMC n Howard Gendelman, M.D.
researchers overcame n Alexander V. Kabanov, Ph.D.
this obstacle with a new n Xinming Liu, Ph.D.
nanoformulation called
LaserART.
LaserART harnesses the power of the patient’s immune system to

store and deliver ART medications throughout the entire body in a
sustained release formulation.
LaserART targets the immune system’s hunter cells, or macrophages,

which roam the body on a perpetual seek and destroy mission looking
for foreign invaders. LaserART piggybacks on the macrophages, which
have full access to all parts of the body, including the central nervous
system—a particularly difficult system to hack for most modern
medicines.
Early tests on mouse models and large animals show that LaserART
produces a sustained release with long-lasting antiretroviral activity.
With further development LaserART could have a dramatic impact on

the estimated 34.2 million people on the planet who are affected by
HIV. The Centers for Disease Control estimates 1.1 million Americans
are living with HIV infection.
Contact:
Matt Boehm
mboehm@unmc.edu
402-559-2166

24 TECHNOLOGY
2020
INFECTIOUS DISEASES PORTFOLIO
Antimicrobial bone scaffold

Infectious Diseases
Improve healing, prevent
infection with 3D bioprinted scaffold
Researchers at the University of
Nebraska Medical Center have Regrow bone tissue
n Biocompatible
invented a novel bone scaffold that
n Supports bone healing
supports healing while simultaneously n Applications include
preventing infections. With the help of craniotomies
the latest 3D bioprinting technology, n Trimmable off-the-shelf
they created a device that is equal or patient-specific
parts regenerative and antimicrobial in n Prevents/manages infec-
one biocompatible package. tions including biofilms
An initial prototype demonstrated INVENTORS

tremendous efficacy in a mouse n Bin Duan, Ph.D.
n Amy Aldrich, Ph.D.
craniotomy model of biofilm infection.
n Mitchell Kuss, Ph.D.
Final product embodiments include n Tammy Kielian, Ph.D.
off-the-shelf and patient-specific
products.
Contact:
Tyler Scherr
402-559-2140
TECHNOLOGY
25
2020
Targeted biofilm prevention
Prevent, treat biofilms by
Infectious Diseases
targeting the immune system
More than a million
cases of hospital-
acquired infections
can be traced to
biofilm, a slimy
coating of microbes
that can form on
medical devices and
implants.
Biofilm infections are

notoriously difficult
to treat without
removing or replacing
the infected medical
device. Treatment is
further hindered by
the development of antibacterial resistant strains of microbes.
But researchers at the University of Nebraska Medical Center

have discovered a new way to combat device-related infections.
Rather than pursue traditional routes of treatment with antibiotics,
Dr. Tammy Kielian has discovered a method to prevent, treat and
destroy biofilms that adhere to implanted medical devices.
Dr. Tammy Kielian has discovered that the inhibition of a certain

population of cells known as myeloid-derived suppressor cells,
enhances the ability of the body’s
immune system to attack and Rundown
clear biofilms. n Minimizes biofilm infections
n Proof of concept in animal
By targeting a patient’s own cells, models
rather than using antibiotics, this
approach may also help decrease Inventor
the likelihood of developing n Tammy Kielian, Ph.D.
antibiotic-resistant bacteria.
Contact:
Matt Boehm
mboehm@unmc.edu
402-559-2166
26 TECHNOLOGY
2020
Antibacterial compounds
Infectious Diseases
New compounds fight
antibiotic resistant bacteria
developed a set of promising antibacterial compounds that can
effectively wipeout bacteria such as MRSA and anthrax.
Antibiotic resistance is a major

health concern. Development
of new and improved drugs is Rundown
n Nanomolar MICs against gram
necessary to fight off antibiotic positive bacteria (MRSA and
resistant strains of bacteria. Anthrax)
n Low micromolar MICs against
The new antibacterial gram negative bacteria
compounds have shown n More potent than vancomycin
some impressive results. and ciprofloxacin
UNMC researchers
developed lead compounds INVENTORS
that were effective in small n Rongshi Li, Ph.D.
concentrations, exhibiting n Ken Bayles, Ph.D.
n Yan Liu, Ph.D.
remarkable nanomolar potency
against MRSA and anthrax.
One compound was tested
against two powerful antibiotics currently available: ciprofloxacin
and vancomycin. The new compound’s potency was similar to
ciprofloxacin against anthrax and was 27 times more potent than
vancomycin against MRSA.
Some of the new compounds also showed broad spectrum activity,

but with low micromolar potency against key Gram-negative
bacteria such as A. baumannii, Enterobacter, and K. pneumonia.
New compounds are also being designed to improve activity
against Gram-negative bacteria.
Researchers are evaluating some of the lead compounds in vivo

against MRSA and anthrax.
Contact:
Matt Boehm
mboehm@unmc.edu
402-559-2166
TECHNOLOGY
27
2020
Antimicrobial peptides
Imbue orthopedic implants
Infectious Diseases
with primary immunity
All orthopedic implants, such as hip or knee replacements,
eventually fail. But if an implant gets infected it fails much more
rapidly and can even lead to death. Researchers at the University
of Nebraska Medical Center discovered a new way to prevent
implant-associated biofilm infections. Guangshun Wang, Ph.D.,
designed antimicrobial peptides to coat the surface of metallic
orthopedic implants and specifically target antibiotic resistant
infections known as MRSA or methicillin-resistant Staphylococcus
aureus. Not only do the novel proteins prevent MRSA biofilm
formation, but they also recruit host immune cells to help clear any
opportunistic bacteria.
Dr. Wang’s technology effectively Rundown

imbues the medical device with its n Highly effective against lead-
own innate immunity. In humans, ing causes of orthopedic
innate immunity represents infections including MRSA
the front line defense against n Ability to prevent bacterial
pathogens. Implants, however, biofilm formation; Formulat-
ed for immobilization unto
have no such basic protections
metal surfaces
against infections, including n Evidence of innate immune
MRSA, which accounts for two- cell recruitment
thirds of all orthopedic implant
infections. Implants can become INVENTOR
unchecked breeding grounds for n Guangshun Wang, Ph.D.
biofilm infections and ultimately
lead to total device replacement—at best.
More than one million Americans receive hip or knee replacements

each year. While about 90 percent of those procedures are still
effective 10 years later, about 100,000 patients will undergo a
repeat procedure to alleviate pain associated with prosthetic
loosening or bacterial infection.
As an opportunistic pathogen, MRSA has evolved numerous

strategies for evading the human immune system. MRSA has a
particularly notorious ability to find, attach to, and create bacterial
biofilms on orthopedic implants. Once a MRSA biofilm is fully
formed, the only effective treatment involves total removal of the
orthopedic implant. Even then, the patient is at a permanently
increased risk for repeat infection.
Contact:
Tyler Scherr
402-559-2140
28 TECHNOLOGY
2020
COVID-19
Hand guard slit lamp shield
New guard protects
Infectious Diseases
opthamologists’ hands
New guard protects opthamologists’ hands
during exams Rundown
n Protects
opthamologists’
An opthalmologist from the University of
hands during an
Nebraska Medical Center has developed a optometric exam
slit lamp shield that can protect the patient n Easy to remove,
and examiner from respiratory droplets clean between
during an opthalmic or optometric exam. patients
This new design of the slit lamp shield
provides excellent coverage of the examiners INVENTOR
hands while retaining its universal use. n Rao Chundry
Slit lamps are an essential piece of any

opthalmic optpmetric exam and this new design will protect the
provider as well as the patience from the transmission of infectious
diseases.
Contact:
Catherine Murari-Kanti
catherine.murari@unmc.edu
402-559-3265
TECHNOLOGY
29
2020
Z-filter Device COVID-19
Captures infectious aerosol
Infectious Diseases
particles during treatments
Clinicians from the University of
Nebraska Medical Center have
developed the Z-filter, a device
that mitigates the release of
infectious aerosolized particles
during nebulizing treatments.
Asthmatic patients or patients

experiencing difficulty breathing
or shortness of breath,
require breathing treatments
delivered via a nebulizer, which
aerosolizes a liquid medication.
The nebulizer allows for faster
and less invasive uptake by
the patient via their respiratory
system. However, in scenarios into the air via the nebulizer’s
where the patient may have high airflow. Many health-care
a highly infectious disease, facilities have stopped all
there is a potential to spread nebulized treatments in fear
of infectious pathogens as the of contaminating rooms with
patient’s breath is dispersed SARS-CoV-2, the coronavirus
responsible for COVID-19.
Rundown The Z-filter is an add-on

n Allows nebulized treatment attachment designed for
in patients with infectious universal fit with standard
diseases oxygen masks that are required
n Prevents environmental con- for nebulizing treatments. Its
tamination construction prevents the
n Preliminary testing exhibits ex- release of exhaled infectious
cellent recapture of aerosolized
particles into the air.
saline
INVENTORS Considering the many

n Heather Nichold upcoming changes in
n Michael Wadman healthcare practices and
n Thang Nguyen procedures, the Z-filter could
n Wesley Zeger become a standard practice in
the future.
Contact:
402-559-3265

30 TECHNOLOGY
2020
COVID-19
Modular Electronic Decision Support Builder
Infectious Diseases
Pediatric interactive screening
tool adapts to institutional needs
Physicians from Omaha’s institutional-level branding and
Children’s Hospital and Medical adjustment of content to fit the
Center have developed a local context.
pediatric-specific COVID-19
screener. This application can Commercial applications
be accessed by a one-time include user data analytics
download as an offline app or and observation, branding and
directly on the web. delivery of content to target
populations, use in public
This tool can be used by a health, and dissemination or
variety of clinical and non- implementation of projects to
clinical end-users to access improve healthcare processes
information step-by-step. The or outcomes. The combination
software also provides tracking of customizable content, user
to connect user behavior with analytics, and interactive
access of tagged content within surveys combines multiple
the tool. The customization distinct features into a single
nature of the tool allows for software tool.
Rundown
n COVID-19 screener specifically
for pediatric patients
n Available as a web-based or
native app
n Allows for institutional-level
branding
INVENTORS
n Ellen Kerns
n Russell McCulloh
Contact:
402-559-3265
TECHNOLOGY
31
2020
COVID-19
COVID-19 Screener
Infectious Diseases
Rapidly screen patients for COVID-19
Clinicians at the University of for other disease states. For
Nebraska Medical Center’s example, this tool could help
Department of Emergency a patient decide if they have a
Medicine have developed a simple case of a sore throat or
patient-focused screening a case of streptococcus. The
platform that allows patients screener then suggests if the
to engage with a screening patient should see a doctor
algorithm that can calculate the or reach for over-the-counter
patient’s risk and probability care based on the severity of
of a COVID-19 diagnosis. This symptoms. This screener, by
technology also provides the steering consumer’s decision
patient with recommendations making process, has the ability
that are specific to their unique to work with local pharmacies
scenario and set of symptoms. and increase foot traffic.
The advantage of this

technology over similar
technologies is that the
clinicians have incorporated Rundown
design logic based on current n Quick assessment based on
medical emergencies that are symptoms
associated with the disease of n Differentiates between emer-
interest. The screening logic is gent, non-emergent scenarios
able to decipher and weed out n Inform, manage patient deci-
emergent cases while providing sion-making
next-step resources to the n Can be modified to fit any
disease state
patient. This patient-consumer
health informatics platform INVENTORS
allows for the development and n Michael Wadman
implementation of consumer n Thang Nguyen
focused technology that n Wesley Zeger
promotes well-being and
optimal health.
The screening tool can be used
Contact:
402-559-3265
32 TECHNOLOGY
2020
COVID-19
Two-part Face Shield
Infectious Diseases
New design
improves PPE adherence
Donning and doffing personal protective equipment can be
cumbersome, and carries with it the risk of potential exposure.
During the on-going COVID-19 pandemic, clinicians are expected
to have a face shield on at all times. They are expected to change
the face shield between each patient visit or in case of a shortage,
decontaminate the shield between visits.
The present face shields are attached to the clinician’s head

by an elastic band. Taking the shield off between each visit is
cumbersome as it could get caught in hair or clothing and thus
increase the risk of infection. To avoid this, clinicians at the
University of Nebraska Medical Center have developed a two-part
face shield that can be easily removed between each patient visit.
In times of shortage, it can be easily decontaminated according to
hospital protocols. This lowers risk because the elastic band stays
on throughout the day, so there is minimal need to touch the head.
Rundown
n User protected from exposure
to disease conditions
n Shield can be re-used under
shortage conditions
n Can be easily de-contaminated
INVENTORS
n Michael Wadman
n Thang Nguyen
n Wesley Zeger
Contact:
402-559-3265
TECHNOLOGY
33
2020
COVID-19
GEMs for COVID-19
Infectious Diseases
Find answers with genetically
engineered mice for SARS-CoV-2
Mouse models could create opportunity for creating a
answers to several lingering versatile set of genetically
unanswered questions about engineered mouse models
the COVID-19 outbreak and the useful for COVID-19 and SARS-
virus that created it, SARS- CoV-2 research.
CoV-2. Geneneticlly engineered
mice will help scientists UNMC researcher,
understand the molecular Channabasaviah Gurumurthy,
mechanisms of the virus, PhD, has developed three
repurpose currently available broad categories of genetically
antiviral drugs, and provide an engineered mouse models,
opportunity to develop new and about 30 different model
therapies and vaccines against designs for SARS-CoV-2
COVID-19. One major challenge research:
in achieving these goals is 1. Knocking-in expression
the lack of suitable preclinical cassettes, or point
animal models. mutations, into the
endogenous mouse ACE2
Unfortunately, SARS-CoV-2 locus.
only infects mice if they express 2. Knocking-in CRE-
human ACE2. This feature, activatable- or tetracycline
combined with a wealth of inducible-hACE2
genetic tools available only expression cassettes into
in mice, offers a unique safe-harbor loci, by re-
engineering the existing
reporter or inducer lines.
Rundown 3. Knocking-in CRE-
n Preclinical mouse models activatable cassettes into
directed towards a variety of the mouse ACE2 locus.
members in the SARS-CoV-2
transmission process The natural non-permissiveness
n Models are generated under
of mice to SARS-CoV-2
different mouse backgrounds
n Research use only infection in combination with a
wide variety of available genetic
INVENTORS tools and molecular switches
n Channabasavaiah Gurumurthy offers a unique opportunity to
n Masato Ohtsukan make this species useful for
n Rolen Quadros COVID-19 research.
Contact:
402-559-3265
34 TECHNOLOGY
2020
COVID-19
Nasopharyngeal Specimen Collection Device
Infectious Diseases
New collection kit simplifies,
improves virus testing accuracy
Clinicians at the University
of Nebraska Medical Center Rundown
have developed a self- n Alternative to traditional naso-
contained specimen container pharangeal swabs
n One-stop solution for gather-
that collects and preserves ing, storing and testing nasal
nasopharyngeal specimens for secretions
testing. n Prototype available for review
The user inserts the collction INVENTORS

device into the patient’s nose n Michael Wadman
and presses the trigger. The n Thang Nguyen
pressure releases saline from n Wesley Zeger
one of two reservoirs, irrigating
the nasal canal.
directly to the laboratory.
The saline then drains into the
second reservoir—the specimen Traditionally, a nurse squirts
chamber—and mixes with saline into a patient’s nose and
a pre-agent to preserve the then inserts a nasal swab for
sample. The user then caps the specimen collection, which
device to seal all the ports and could lead to false negative
to prevent leakage. test results. The new sample
collection device prevents the
The entire device is then type of false negatives that
transported to the laboratory for occur due to improper washing
the appropriate tests. of the nasal passages.
The sample collection device The device could be used in

could be mailed directly to the clinic to test for a variety of
patients so they can take the viruses like SARS-CoV-2 and
test in the privacy of their the more common influenza
homes. The patient would viruses.
then mail the sample chamber
Contact:
402-559-3265
TECHNOLOGY
35
2020
COVID-19
SARS-CoV-2 antigens & serological assay
Novel antigens could help
Infectious Diseases
detect, fight coronavirus

have identified SARS-CoV-2 n Custom antigens can be used
protein antigens to help develop to develop diagnostics and
therapeutics and diagnostics for therapeutics for COVID-19
COVID-19. n Antigens show specificity and
selectivity for SARS-CoV-2
The researchers have generated antibodies
n Serologic assay shows high
custom-designed viral protein
sensitivity and low background
sequences and expression
constructs to serve as antigens INVENTORS
in serological assays. Initial n Andrew Schnaubelt
testing has shown the antigens n Chittibabu Guda
can be used to differentiate n Gloria Borgstahl
between COVID-19 positive n Ken Bayles
and COVID-19 negative n Mara Jana Broadhurst
n Siddappa Byareddy
patient samples. The proof-of-
n St Patrick Reid
concept serological assay using
the antigens demonstrated
sensitivity and specificity for in the design of therapeutics
SARS-CoV-2 antibodies in for the treatment of COVID-19
serum and plasma. including antibody-based
therapeutics as well as
The antigens can also be used vaccines.
Contact:
Matt Boehm
mboehm@unmc.edu
402-559-2166

36 TECHNOLOGY
2020
COVID-19
PAPR Adapter
Infectious Diseases
3D print file creates adapter for
previously incompatible systems
Clinicians at the University of

Nebraska Medical Center and
its clinical partner, Nebraska
Medicine, developed a new Rundown
n Simple adapter can be
solution to chronic shortages 3D-printed
caused by the COVID-19 n Maximize a hospital’s Powered
pandemic. In this case, they Air Purifying Respirator fleet
created a simple adapter that n Adapter connects 3M Versa-
can be 3D-printed and used to flow air handling unit with a
maximize a hospital’s Powered Dover brand Hood
Air Purifying Respirator fleet, or n Print file available on request
PAPR for short. INVENTORS
n Jerald Farke
The adapter enables hospitals n Nicholas Markin
and other clinical setting to n Tyler Scherr
connect a 3M Versaflow air
handling unit with a Dover brand
Hood.
Contact:
Tyler Scherr
402-559-2140
TECHNOLOGY
37
2020
COVID-19
3D-Printed Nasal Swabs
Overcome shortages with
Infectious Diseases
additive manufacturing
developed a new
solution to chronic
shortages caused
by the COVID-19
pandemic. In
particular, the
inventors created a
new type of nasal
swab that can be
used to collect patient
samples for testing
various contagions,
including the novel
coronavirus.
The nasopharyngeal
swab can be rapidly
produced at a relatively low-
cost using a filament-based Rundown
3D-printer.The swabs are also n Cost-effect solution to pan-
demic-related shortages
printed in such a way that n Clinical testing proves 3D
gives the swab a reliable tensile swabs just as effective as
strength that reduces the chance cotton
of it breaking during a procedure. n Print files available upon
request
Currently in use at Nebraska n Licensing opportunities for
Medicine, UNMC’s clinical more advanced version also
partner, the swabs were printed available
using polyethylene terephthalate
INVENTOR
glycol filament, a food- n Jesse Cox
grade plastic that is relatively
inexpensive and widely available.
Further, PETG is a thermoplastic polyester that is durable,
chemically inert and well suited for structural applications.
Clinical testing showed that the printed swabs were just as

effective and reliable as more traditional versions already on the
market.
Contact:
Tyler Scherr
402-559-2140
38 TECHNOLOGY
2020
COVID-19
Infectious aerosol filter housing
Reusable housing
Infectious Diseases
allows replacement filters
Virus filters are commonly
used to prevent patients from
dispersing virus-containing
droplets when receiving oxygen
therapy, or during intubation
procedures that use ventilators
to help the patients breathe.
But during a pandemic like the
COVID-19 outbreak, supplies of
the typically disposable single-
use filters become scarce.
Innovators at the University The filter housing can also

of Nebraska Medical Center be fitted to any tube system,
developed a replacement including ventilators. It also
filter housing that can be comes in various sizes and
cleaned and opened so that shapes to accommodate
replacement filter paper can be virtually any need for in-line
inserted. filtered tubing systems.
Rundown
n Overcomes filter scarcity during
pandemics like COVID-19
n Can be cleaned and reused
n Can accommodate any tubing
system
n Several sizes and shapes are
also available
INVENTORS
n Greg Pugh
n James Linder
n Max Kaeter
n Nicholas Markin
n Steven Lisco
Contact:
Tyler Scherr
402-559-2140
TECHNOLOGY
39
2020
Infectious Aerosol Capture Mask COVID-19
New device protects
Infectious Diseases
caregivers from viral exposure
A new protective device can “catching more than 90 percent of
help protect healthcare workers airborne particles expelled in the
everywhere, preventing infected mask, ultimately preventing the
patients from spraying or exhaling aerosol from entering the patient
viral agents and potentially environment.” He added: “Even
infecting others in the room. when the vacuum wasn’t turned
on, the mask was still 85 percent
Aerosol capture maskDeveloped effective as a barrier.”
by the chair of UNMC’s
Department of Anesthesiology, At this initial stage, the special
Steven Lisco, M.D., the Infectious adapter for the Infectious Aerosol
Aerosol Capture Mask is a face Capture Mask is available
tent that covers the patient’s for purchase through Omaha
mouth and nose, and is then Custom Manufacturing at info@
coupled with a viral filter and a omahacustommfg.com or 800-
special adapter that connects the 228-5021. All other components
unit to standard vacuum supplies are commonly accessible in
in most clinical settings. most clinical settings and readily
found through various medical
The Nebraska Medicine Innovation equipment suppliers.
Committee has approved the
device for use in its facilities, and A future version of the technology
has already deployed them in will incorporate all components
operating rooms and elsewhere in into one contiguous device,
the hospital. but that will not be available for
purchase until later this year.
Hospitals risk wider contamination
from COVID-19 patients when they
cough or even just breathe. They Rundown
produce microscopic particles that n Limits caregiver exposure to
float through the air of their rooms, aerosolized viral agents
and potentially beyond. Even n Covers the patient’s mouth and
patients that have no symptoms nose
may still unwittingly spread the n Assembled from commonly
virus in the same way, particularly available products in clinical
when wearing supplemental settings
oxygen or undergoing the n Universal adapter connects to
procedures that insert or remove standard vacuum line found in
breathing tubes. most clinical settings
Dr. Lisco said in a recent INVENTORS

announcement the device n Nicholas Markin
performed well in early tests, n Steven Lisco
Contact:
Tyler Scherr
402-559-2140
40 TECHNOLOGY
2020
COVID-19
Vaccine Platform
New strategy to prevent viral
Infectious Diseases
infections, including coronavirus
Researchers at the University against known and emerging

of Nebraska Medical Center viral pathogens. The system
have developed a modular can rapidly generate vaccine
vaccine system that can be candidates and allows for
used to generate vaccines the incorporation of multiple
peptide-based antigens from a
virus of interest or from multiple
Rundown viruses. Since multiple antigens
n System rapidly generates can be combined in one
vaccine candidates vaccine, it can help increase
n Incorporates multiple pep-
tide-based antigens
the efficacy of vaccines against
n Increases vaccine efficacy emerging viral diseases.
against emerging viral dis-
eases Researchers are exploring the
n Potential use for COVID-19 use of this new vaccine system
(SARS-CoV-2), SARS (SARS- for emerging viral diseases such
CoV-1), MERS, Ebola, Influen- as COVID-19 (SARS-CoV-2),
za A and Influenza B SARS (SARS-CoV-1), MERS
and Ebola, as well as for the
INVENTORS production of vaccines against
n Karen Zagorski
n Yuri Lyubchenko
well-known viral pathogens
such as Influenzas A and B.
Contact:
Matt Boehm
mboehm@unmc.edu
402-559-2166
TECHNOLOGY
41
2020
COVID-19
Intubation Shield
Protect providers from COVID-19
Infectious Diseases
In response to
the COVID-19
pandemic, a
new intubation
box developed
at the University
of Nebraska
Medical Center,
helps protect
healthcare
workers by
shielding them
from exposure
to various
contagions and
contaminants*.
The lightweight contact Cori Harsh at charsh@

material stores flat and can be unmc.edu.
assembled in seconds. It fits
around the patient’s head and *Note: These statements have not been evaluated
neck area while providing a care by the Food and Drug Administration. These
products are not intended to diagnose, treat, cure
provider with enough space or prevent any disease.
and access to safely perform
intubation procedures.
Rundown
The UNMC Intubation Shield n Lightweight, assembles in
seconds
is available for purchase, with
n Clear plastic lies flat when not
special discounts available for in use
bulk purchases. Three sizes n Can be sanitized for multiple
are available: standard, large uses
pediatric and small pediatric. n Care instructions: Do not clean
Prices are steeply discounted with petroleum- or ammo-
due to the obvious need. nia-based products, such as
Regular price was $300, but Windex. Use only UV, bleach
indivdual units will be sold water or soapy water.
n Available in three sizes: Adult
at $150 until the pandemic
(24-inches tall), pediatric-large
subsides. Bulk orders of five or (14-in.) and pediatric-small
more are $100 each. Prices do (11-in.)
not include shipping. To order,
Contact:

TECHNOLOGY
2020
cancer PORTFOLIO
cardiovascular
drug delivery
infectious diseases
medical devices
metabolic
miscellaneous
neurologic
research tools
software
startups
TECHNOLOGY
43
2020
PORTFOLIO MEDICAL DEVICES
COVID-19
Intubation Shield
Protect providers from COVID-19
Medical Devices
In response to
the COVID-19
pandemic, a
new intubation
box developed
at the University
of Nebraska
Medical Center,
helps protect
healthcare
workers by
shielding them
from exposure
to various
contagions and
contaminants*.
The lightweight contact Cori Harsh at charsh@

material stores flat and can be unmc.edu.
assembled in seconds. It fits
around the patient’s head and *Note: These statements have not been evaluated
neck area while providing a care by the Food and Drug Administration. These
products are not intended to diagnose, treat, cure
provider with enough space or prevent any disease.
and access to safely perform
intubation procedures.
Rundown
The UNMC Intubation Shield n Lightweight, assembles in
seconds
is available for purchase, with
n Clear plastic lies flat when not
special discounts available for in use
bulk purchases. Three sizes n Can be sanitized for multiple
are available: standard, large uses
pediatric and small pediatric. n Care instructions: Do not clean
Prices are steeply discounted with petroleum- or ammo-
due to the obvious need. nia-based products, such as
Regular price was $300, but Windex. Use only UV, bleach
indivdual units will be sold water or soapy water.
n Available in three sizes: Adult
at $150 until the pandemic
(24-inches tall), pediatric-large
subsides. Bulk orders of five or (14-in.) and pediatric-small
more are $100 each. Prices do (11-in.)
not include shipping. To order,
Contact:

44 TECHNOLOGY
2020
MEDICAL DEVICES PORTFOLIO
COVID-19
Infectious aerosol filter housing
Reusable housing
Medical Devices
allows replacement filters
Virus filters are commonly
used to prevent patients from
dispersing virus-containing
droplets when receiving oxygen
therapy, or during intubation
procedures that use ventilators
to help the patients breathe.
But during a pandemic like the
COVID-19 outbreak, supplies of
the typically disposable single-
use filters become scarce.
Innovators at the University The filter housing can also

of Nebraska Medical Center be fitted to any tube system,
developed a replacement including ventilators. It also
filter housing that can be comes in various sizes and
cleaned and opened so that shapes to accommodate
replacement filter paper can be virtually any need for in-line
inserted. filtered tubing systems.
Rundown
n Overcomes filter scarcity during
pandemics like COVID-19
n Can be cleaned and reused
n Can accommodate any tubing
system
n Several sizes and shapes are
also available
INVENTORS
n Greg Pugh
n James Linder
n Max Kaeter
n Nicholas Markin
n Steven Lisco
Contact:
Tyler Scherr
402-559-2140
TECHNOLOGY
45
2020
Infectious Aerosol Capture Mask COVID-19
New device protects
Medical Devices
caregivers from viral exposure
A new protective device can “catching more than 90 percent of
help protect healthcare workers airborne particles expelled in the
everywhere, preventing infected mask, ultimately preventing the
patients from spraying or exhaling aerosol from entering the patient
viral agents and potentially environment.” He added: “Even
infecting others in the room. when the vacuum wasn’t turned
on, the mask was still 85 percent
Aerosol capture maskDeveloped effective as a barrier.”
by the chair of UNMC’s
Department of Anesthesiology, At this initial stage, the special
Steven Lisco, M.D., the Infectious adapter for the Infectious Aerosol
Aerosol Capture Mask is a face Capture Mask is available
tent that covers the patient’s for purchase through Omaha
mouth and nose, and is then Custom Manufacturing at info@
coupled with a viral filter and a omahacustommfg.com or 800-
special adapter that connects the 228-5021. All other components
unit to standard vacuum supplies are commonly accessible in
in most clinical settings. most clinical settings and readily
found through various medical
The Nebraska Medicine Innovation equipment suppliers.
Committee has approved the
device for use in its facilities, and A future version of the technology
has already deployed them in will incorporate all components
operating rooms and elsewhere in into one contiguous device,
the hospital. but that will not be available for
purchase until later this year.
Hospitals risk wider contamination
from COVID-19 patients when they
cough or even just breathe. They Rundown
produce microscopic particles that n Limits caregiver exposure to
float through the air of their rooms, aerosolized viral agents
and potentially beyond. Even n Covers the patient’s mouth and
patients that have no symptoms nose
may still unwittingly spread the n Assembled from commonly
virus in the same way, particularly available products in clinical
when wearing supplemental settings
oxygen or undergoing the n Universal adapter connects to
procedures that insert or remove standard vacuum line found in
breathing tubes. most clinical settings
Dr. Lisco said in a recent INVENTORS

announcement the device n Nicholas Markin
performed well in early tests, n Steven Lisco
Contact:
Tyler Scherr
402-559-2140
46 TECHNOLOGY
2020
COVID-19
Nasopharyngeal Specimen Collection Device
New collection kit simplifies,
Medical Devices
improves virus testing accuracy
Clinicians at the University
have developed a self- n Alternative to traditional naso-
contained specimen container pharangeal swabs
n One-stop solution for gather-
that collects and preserves ing, storing and testing nasal
nasopharyngeal specimens for secretions
testing. n Prototype available for review
The user inserts the collction INVENTORS

device into the patient’s nose n Michael Wadman
and presses the trigger. The n Thang Nguyen
pressure releases saline from n Wesley Zeger
one of two reservoirs, irrigating
the nasal canal.
directly to the laboratory.
The saline then drains into the
second reservoir—the specimen Traditionally, a nurse squirts
chamber—and mixes with saline into a patient’s nose and
a pre-agent to preserve the then inserts a nasal swab for
sample. The user then caps the specimen collection, which
device to seal all the ports and could lead to false negative
to prevent leakage. test results. The new sample
collection device prevents the
The entire device is then type of false negatives that
transported to the laboratory for occur due to improper washing
the appropriate tests. of the nasal passages.
The sample collection device The device could be used in

could be mailed directly to the clinic to test for a variety of
patients so they can take the viruses like SARS-CoV-2 and
test in the privacy of their the more common influenza
homes. The patient would viruses.
then mail the sample chamber
Contact:
402-559-3265
TECHNOLOGY
47
2020
COVID-19
3D-Printed Nasal Swabs
Overcome shortages with
Medical Devices
additive manufacturing
developed a new
solution to chronic
shortages caused
by the COVID-19
pandemic. In
particular, the
inventors created a
new type of nasal
swab that can be
used to collect patient
samples for testing
various contagions,
including the novel
coronavirus.
The nasopharyngeal
swab can be rapidly
produced at a relatively low-
cost using a filament-based Rundown
3D-printer.The swabs are also n Cost-effect solution to pan-
demic-related shortages
printed in such a way that n Clinical testing proves 3D
gives the swab a reliable tensile swabs just as effective as
strength that reduces the chance cotton
of it breaking during a procedure. n Print files available upon
request
Currently in use at Nebraska n Licensing opportunities for
Medicine, UNMC’s clinical more advanced version also
partner, the swabs were printed available
using polyethylene terephthalate
INVENTOR
glycol filament, a food- n Jesse Cox
grade plastic that is relatively
inexpensive and widely available.
Further, PETG is a thermoplastic polyester that is durable,
chemically inert and well suited for structural applications.
Clinical testing showed that the printed swabs were just as

effective and reliable as more traditional versions already on the
market.
Contact:
Tyler Scherr
402-559-2140
48 TECHNOLOGY
2020
COVID-19
Two-part Face Shield
New design
Medical Devices
improves PPE adherence
Donning and doffing personal protective equipment can be
cumbersome, and carries with it the risk of potential exposure.
During the on-going COVID-19 pandemic, clinicians are expected
to have a face shield on at all times. They are expected to change
the face shield between each patient visit or in case of a shortage,
decontaminate the shield between visits.
The present face shields are attached to the clinician’s head

by an elastic band. Taking the shield off between each visit is
cumbersome as it could get caught in hair or clothing and thus
increase the risk of infection. To avoid this, clinicians at the
University of Nebraska Medical Center have developed a two-part
face shield that can be easily removed between each patient visit.
In times of shortage, it can be easily decontaminated according to
hospital protocols. This lowers risk because the elastic band stays
on throughout the day, so there is minimal need to touch the head.
Rundown
n User protected from exposure
to disease conditions
n Shield can be re-used under
shortage conditions
n Can be easily de-contaminated
INVENTORS
n Michael Wadman
n Thang Nguyen
n Wesley Zeger
Contact:
402-559-3265
TECHNOLOGY
49
2020
COVID-19
PAPR Adapter
3D print file creates adapter for
Medical Devices
previously incompatible systems
Clinicians at the University of

Nebraska Medical Center and
its clinical partner, Nebraska
Medicine, developed a new Rundown
n Simple adapter can be
solution to chronic shortages 3D-printed
caused by the COVID-19 n Maximize a hospital’s Powered
pandemic. In this case, they Air Purifying Respirator fleet
created a simple adapter that n Adapter connects 3M Versa-
can be 3D-printed and used to flow air handling unit with a
maximize a hospital’s Powered Dover brand Hood
Air Purifying Respirator fleet, or n Print file available on request
PAPR for short. INVENTORS
n Jerald Farke
The adapter enables hospitals n Nicholas Markin
and other clinical setting to n Tyler Scherr
connect a 3M Versaflow air
handling unit with a Dover brand
Hood.
Contact:
Tyler Scherr
402-559-2140
50 TECHNOLOGY
2020
COVID-19
Hand guard slit lamp shield
New guard protects
Medical Devices
opthamologists’ hands
New guard protects opthamologists’ hands
during exams Rundown
n Protects
opthamologists’
An opthalmologist from the University of
hands during an
Nebraska Medical Center has developed a optometric exam
slit lamp shield that can protect the patient n Easy to remove,
and examiner from respiratory droplets clean between
during an opthalmic or optometric exam. patients
This new design of the slit lamp shield
provides excellent coverage of the examiners INVENTOR
hands while retaining its universal use. n Rao Chundry
Slit lamps are an essential piece of any

opthalmic optpmetric exam and this new design will protect the
provider as well as the patience from the transmission of infectious
diseases.
Contact:
402-559-3265
TECHNOLOGY
51
2020
Z-filter Device COVID-19
Captures infectious aerosol
Medical Devices
particles during treatments
Clinicians from the University of
developed the Z-filter, a device
that mitigates the release of
infectious aerosolized particles
during nebulizing treatments.
Asthmatic patients or patients

experiencing difficulty breathing
or shortness of breath,
require breathing treatments
delivered via a nebulizer, which
aerosolizes a liquid medication.
The nebulizer allows for faster
and less invasive uptake by
the patient via their respiratory
system. However, in scenarios into the air via the nebulizer’s
where the patient may have high airflow. Many health-care
a highly infectious disease, facilities have stopped all
there is a potential to spread nebulized treatments in fear
of infectious pathogens as the of contaminating rooms with
patient’s breath is dispersed SARS-CoV-2, the coronavirus
responsible for COVID-19.
Rundown The Z-filter is an add-on

n Allows nebulized treatment attachment designed for
in patients with infectious universal fit with standard
diseases oxygen masks that are required
n Prevents environmental con- for nebulizing treatments. Its
tamination construction prevents the
n Preliminary testing exhibits ex- release of exhaled infectious
cellent recapture of aerosolized
particles into the air.
saline
INVENTORS Considering the many

n Heather Nichold upcoming changes in
n Michael Wadman healthcare practices and
n Thang Nguyen procedures, the Z-filter could
n Wesley Zeger become a standard practice in
the future.
Contact:
402-559-3265

52 TECHNOLOGY
2020
Antimicrobial bone scaffold

Improve healing, prevent
Medical Devices
infection with 3D bioprinted scaffold
Researchers at the University of
Nebraska Medical Center have Regrow bone tissue
n Biocompatible
invented a novel bone scaffold that
n Supports bone healing
supports healing while simultaneously n Applications include
preventing infections. With the help of craniotomies
the latest 3D bioprinting technology, n Trimmable off-the-shelf
they created a device that is equal or patient-specific
parts regenerative and antimicrobial in n Prevents/manages infec-
one biocompatible package. tions including biofilms
An initial prototype demonstrated INVENTORS

tremendous efficacy in a mouse n Bin Duan, Ph.D.
n Amy Aldrich, Ph.D.
craniotomy model of biofilm infection.
Final product embodiments include n Tammy Kielian, Ph.D.
off-the-shelf and patient-specific
products.
Contact:
Tyler Scherr
402-559-2140
TECHNOLOGY
53
2020
Intubation Shield
Protect providers from
Medical Devices
COVID-19 outbreak
In response to the COVID-19 Bulk orders of five or more are
pandemic, a new intubation box $100 each. Prices do not include
developed at the University of shipping.
Nebraska Medical Center, helps
protect healthcare workers by Learn more at https://www.
shielding them from exposure unemed.com/product/intubation-
to various contagions and box.
contaminants*.
*Note: These statements have not
The lightweight material stores flat been evaluated by the Food and Drug
and can be assembled in seconds. Administration. These products are not
intended to diagnose, treat, cure or
It fits around the patient’s head prevent any disease.
and neck area while providing a
care provider with enough space
and access to safely perform Rundown
intubation procedures. n Lightweight, assembles in sec-
onds
The UNMC Intubation Shield n Clear plastic lies flat when not in
is available for purchase, with use
special discounts available for n Can be sanitized for multiple uses
bulk purchases. Prices are steeply
discounted due to the obvious Care instructions
need. Regular price was $300, n Clean the surface using a
but indivdual units will be sold at 100% cotton cloth and soapy
$150 until the pandemic subsides. water. Rinse with clean water.
n UV light, alcohol or a mild
bleach and water solution can
also be used.
n Do not use Windex or clean-
ers with petroleum products
listed in the ingredients. They
may cause the polycarbonate
to weaken and crack.
To Order
n Email Cori Harsh at charsh@
unmc.edu
n Cost is $150 plus shipping
for one. Bulk orders of five or
more are $100 per shield, plus
shipping. Will be shipped from
Omaha, Nebraska.
Contact:

54 TECHNOLOGY
2020
Fall risk assessment insole

Predict fall risk to prevent injuries
Medical Devices
Slips and falls are random.
But we know several Rundown
risk factors that make n One-third of adults older than 65 fall
falling down much more each year
likely. Risk factors include n Two-thirds of adults older than 65
advancing age, visual have been hospitalized after a fall
impairments, muscle n Portable insole assesses risk of
weakness and even prior falling in minutes
n Fall risk can be assessed with 90
hospitalization.
percent specificity
A special insole and a INVENTOR
proprietary algorithm could n Arash Gonabadi, Ph.D.
help physicians more n Max Kurz, Ph.D.
accurately predict the n Nicholas Stergiou, Ph.D.
likelihood of falling, and n Philippe Malcolm, Ph.D.
help prevent serious injuries
to elderly patients in particular.
Nick Stergiou, Ph.D., and his colleagues in the biomechanics

department at the University of Nebraska at Omaha, developed
such a device—the insole and the accompanying algorithm—for
fall-risk assessment. The portable, wireless device can be easily
worn to collect critical biometric data after a few minutes of
walking. The data can
be stored on the device
and transferred to the
program via USB, or
uploaded wirelessly to
the cloud.
The current prototype

assesses fall risk in a
small population with
90 percent specificity.
The research team
believes they can
refine the algorithm
to increase specificity
even further with a
larger sample size.
Contact:
Tyler Scherr
402-559-2140
TECHNOLOGY
55
2020
Hybrid arm
One device combines best of body-
Medical Devices
powered, motor-driven prostheses
A new cyborg
prosthetic arm design
brings prosthetics
one step closer to
replicating anatomy.
Traditional
electronically-powered
prostheses have two
common downfalls:
weight and a lack of
manual, body-powered
control.
To solve these issues, a research team at UNO Biomechanics

designed a novel prosthetic arm that incorporates the best of
both worlds: It has both the lightweight feel of a body-powered
prosthetic and the improved functionality of an electronically-
powered device.
Using a body-powered prosthetic base, the hybrid arm still

provides manual control.
Manual motor control is an important feature because it permits the

development of healthy and strong muscles in children who would
normally abandon the use of their affected limb. That leads to long-
term weakness and even postural
problems such as scoliosis. Rundown
n Strategically combines
To reduce weight and enhance ease body-powered and motor-
of use, fewer (and lighter-weight) driven actuation
motors are used. n Lightweight
n Ergonomic
Rather than developing all of the n Decreased muscle fatigue
force needed to grip objects, INVENTORS
the motors in this hybrid design n James Pierce
are intended to augment the n Jean Peck
user’s strength to make using the n Jorge Zuniga, Ph.D.
prosthetic easier and to encourage n Rakesh Srivastava
them to use the strength they have. n Walker Arce
Contact:
Tyler Scherr
402-559-2140
56 TECHNOLOGY
2020
Wound irrigation system

Faster, easier wound-cleaning
Medical Devices
with continuous spray control
Inspired by their frustrations of
repeatedly plunging a syringe
into a sterile solution to spray
a wound, emergency room
personnel at UNMC found a way
to save time and energy with
a new irrigation system called
“Wadwand.”
Wound cleaning is an art where

the doctor or nurse must pour
the sterile saline solution into
a basin, load the solution into
a syringe, and spray the liquid
from the syringe with the same force and consistency each time.
This method produces inconsistent amounts of pressure,

particularly for deep wounds, which require much greater amounts
of saline pressure.
The Wadwand uses a standard sterile solution bottle fitted with

a specialized cap that hooks up to a uniquely designed irrigation
wand. Providers are then able to initiate the flow of the saline
solution and adjust the fluid
pressure with the press of a
Rundown finger.
n Fitted to a sterile solution The inventors have also
n Ergonomic design
n Cost-efficient
developed a portable
n Adjustable fluid pressure version that allows the user
n Continuous wound irrigation to clean wounds outside a
n Improve wound cleansing healthcare facility.
n Faster irrigation process
UNeMed is seeking a
INVENTORS partner to complete
n Michael Wadman, M.D. preclinical testing and help
n Thang Nguyen, A.P.R.N., M.S.L. place a Wadwand irrigation
n Vincent Morris, A.P.R.N. system in ERs across the
n Richard Morris
nation.
Contact:
402-559-3265
TECHNOLOGY
57
2020
Modular prosthetic arm
Prosthetics adapts to lifestyle
Medical Devices
A modular prosthetic arm, invented at UNO Biomechanics, is body-
powered, lightweight and made to accommodate a smorgasbord
of task-specific end-effector attachments. The end-effectors are
specially engineered to perform specific, challenging tasks such
as playing a stringed instrument, swimming, riding a bike, and
participating in team sports like basketball and baseball.
The end-effectors can be easily removed and replaced as needed

so active users can easily move from one task to the next.
Brendan Sullivan/Omaha World-Herald

Lincoln fourth-grader Peyton Tiernan can now play the cello with a pros-
thesis design by a UNO team — am arm with a clamp on the end that locks
onto the bow.
Read the full article at: https://www.omaha.com/livewellnebraska/
inspiration/lincoln-boy-learns-cello-with-help-from-a-uno-designed/
article_5baf4226-d347-5e6e-a95b-ae1273b6a3a3.html
Contact:
Tyler Scherr
402-559-2140
58 TECHNOLOGY
2020
Short nanofiber formulations for bone defects

Nanofiber formulation
Medical Devices
provides versatile approach
to treating bone defects
Researchers at the University of administration.
developed a nanofiber-based These short nanofibers have
therapy for the treatment of performed exceptionally well
bone defects. in repairing periodontal injuries
in rats following molar tooth
This therapy consists of extraction.
mineralized short nanofiber
fragments that are conjugated Additionally, the short
to BMP-2 mimicking peptides. nanofibers can be used as
These short nanofiber a platform technology for
fragments are easy to delivering other therapeutic
manufacture and can be made agents instead of BMP-2. Work
from a variety of polymers. is being done to develop short
They are versatile and can nanofiber formulations for
be formulated into powders, treating hemorrhage and soft
gels, and sprays for easy tissue injuries.
Rundown
n Highly customizable scaffold
for bone tissue regeneration
n May be formulated with addi-
tional therapeutics for targeted
therapy
n Biodegradable
INVENTORS
n Jingwei Xie
n Sunil Kumar Boda
Contact:
Matt Boehm
mboehm@unmc.edu
402-559-2166
TECHNOLOGY
59
2020
Ergonomic surgical loupe head strap

Doctors no longer need to
Medical Devices
sacrifice precision for comfort
A new head
strap for
surgical
magnifying
eyeglasses—
or surgical
loupes—will
relieve strain
and fatigue
for surgeons,
clearing the
way for more
accurate
and efficient
procedures.
The new design

removes the
weight of
cumbersome
surgical loupes
from the nasal bridge and ears, and redistributes the burden evenly
across the head. The ergonomic surgical loupes head strap relieves
the pain associated with poor
posture and long procedures.
Rundown It is easy to use, and fastens
n Comfortably redistributes
weight from nasal bridge comfortably and securely to the
n Easily adjustable, one size user’s head.
fits most
n Securely holds surgical A leading pediatric ophthalmologist
loupes in place at the University of Nebraska
Medical Center, Donny Suh,
INVENTOR M.D., and a local inventor, James
n Donny Suh, M.D. Hermsen, teamed up to invent the
n James Hermsen
device.
Contact:
Tyler Scherr
402-559-2140

60 TECHNOLOGY
2020
Tissue regeneration scaffold

Nanofiber technology enhances
Medical Devices
wound healing, tissue regeneration
A new expanded nanofiber-
based scaffold will help enhance
tissue growth and regeneration
within the body.
Invented at the University of

Nebraska Medical Center,
expanded nanofiber scaffolds
can be customized to various
shapes and dimensions allowing
them to better fit within wounds
and tissue defects. The new
scaffolds are layered with a
highly porous structure that
allows optimal cell and tissue
growth, compared to traditional
nanofiber materials. The
expanded nanofiber scaffolds
are manufactured to contain
an array of wells, or holes, for
placing cells or minced tissue,
which helps jump-start the
tissue repair process. Rundown
n Made out of biodegradable
The nanofiber scaffolds were and biocompatible expanded
tested in preliminary in vivo nanofibers
studies. The scaffolds were n Enhanced cell infiltration
implanted subcutaneously n Size and shape of the nanofiber
in rats for one, two, and four scaffold is customizable
weeks. Cellular infiltration
INVENTORS
occurred throughout the
n Jingwei Xie, Ph.D.
scaffold, along with blood vessel n Mark Carlson, M.D.
formation.
Contact:
Matt Boehm
mboehm@unmc.edu
402-559-2166
TECHNOLOGY
61
2020
Medical Devices
Distal radius fracture plating system
Universal plating system
saves time, improves outcomes
Wrist fractures don’t come in
one shape and size, but a new
fixation device just might. A leading
orthopedic surgeon at the University
of Nebraska Medical Center, Daniel
Firestone, M.D., invented a universal
wrist fracture fixation plate. By Rundown
studying fragment-specific plating n Universal plate for distal
systems, Dr. Firestone designed a radius fractures
novel plate that blends the essential n Benefit of optimal
components of each. The result is an fragment fixation systems
elegant system with enough flexibility n Benefit of surgeon comfort
to secure any of the most common with the procedure
wrist fracture patterns. n Replaces, combines
several plating systems
The Firestone Plating System is into one
a next-generation technology INVENTOR
that provides all of the benefits of n Daniel Firestone, M.D.
fragment specific plating without
the drawbacks associated with
surgically placing multiple devices. It
singlehandedly addresses a number
of fractures in both dorsal and volar
fragments. It’s is easy to use and
easier to install, potentially increasing
operating room and surgical
efficiency.
Contact:
Tyler Scherr
402-559-2140

62 TECHNOLOGY
2020
MedLens
Upgrade any smartphone
Medical Devices
into a diagnostic tool
MedLens is a versatile attachment that

fits any smartphone, upgrading it into a
diagnostic tool, such as a fundoscope
or otoscope. MedLens can be quickly
and easily attached to a smartphone and
positioned over the camera lens using a
simple rail-and-clamp system.
Once in place, the modular lens package

design allows for multiple anatomical
imaging applications. Users can
even control the level of illumination
for perfect contrast no matter the
application.
This new device saves

Rundown clinicians time and
n Flexible fit for several smartphone
models money, particularly in
n Modular lens packages for multiple outreach or out-of-
anatomical imaging applications clinic settings. It also
n Illumination control for perfect provides clinicians with a
contrast no matter the application convenient way to record
images and share them
INVENTORS for further diagnostic
n Donny Suh, M.D. examination and second
n Jesse Cox
opinions.
Contact:
Joe Runge
hrunge@unmc.edu
402-559-1181
TECHNOLOGY
63
2020
Endovascular training
New manikin improves training
Medical Devices
for endovascular procedures
Researchers at
the University of
Nebraska Medical
Center developed
a simulation
manikin for vascular
procedures to
help physicians,
residents, and
medical students
improve skills and
test medical devices.
The simulation
manikin replicates
the vascular system,
including special
valves for controlled
bleeding and a life-like pulse. The vascular system can be swapped
out so users can practice on various anatomies such as healthy
vascular systems with specific diseases or disorders—aortic
dissections, aortic aneurysms and plaques.
The manikin also contains a module that allows the practice of

gaining access to a groin artery.
The access module can be used
multiple times without leaking and is Rundown
n Accurate model of human
compatible with ultrasound imaging.
vasculature
n Mimics blood flow
The system can be opened, allowing n Contains training module
users to see the procedures as they for vascular access
practice. Or, the system can be fully n Useful for testing new
enclosed and used in combination medical devices
with standard imaging technology
such as fluoroscopy and ultrasound. INVENTORS
n Jason MacTaggart
This system is also ideal for testing n Alexey Kamenskiy
n Paul Deegan
new medical devices such as stents,
n Ethan Monhollon
grafts and balloon catheters.
Contact:
Matt Boehm
mboehm@unmc.edu
402-559-2166
64 TECHNOLOGY
2020
Antimicrobial wound dressing

Improved wound dressings for
Medical Devices
treating, preventing infections
A new wound dressing with
antimicrobial properties can Rundown
n slowly releases antimicrobial
improve the treatment of
compounds
chronic wounds. n penetrates biofilms, enhances
animicrobial delivery
Patients with chronic open n may eliminate need for tissue
wounds, such as diabetic foot removal
ulcers, have about a 78 percent
incidence rate of serious INVENTORS
infections known as biofilms. n Gus Wang
Biofilms are cooperative n Jingwei Xie
infections that are often difficult
to treat due to high rates of
antibiotic resistance. nitrate, into a wound to help
prevent or treat an infection.
Current approaches to biofilm The nanofiber dressings are
management heavily rely on the specially designed to help
physical removal of infected penetrate biofilms and enhance
tissue. This removal process delivery of antimicrobial agents.
can be uncomfortable for Additionally, these wound
patients, and may not entirely dressings may require fewer
remove the infection, requiring changes and may reduce or
the painful procedure to be even eliminate the need for
repeated. tissue removal.
UNMC’s nanofiber-based These new nanofiber dressings
dressing slowly releases should help decrease biofilm
antimicrobial compounds such infections, reduce medical
as approved antibiotics or silver costs, and improve patient care.
Contact:
Matt Boehm
mboehm@unmc.edu
402-559-2166
TECHNOLOGY
65
2020
Sympathetic vasomotion monitoring

New device will improve outcomes
Medical Devices
in renal denervation procedures
Researchers at UNMC developed a
device capable of making high blood Rundown
n Detects small changes
pressure more treatable by accurately
n Measures success of
measuring the rhythmic constriction renal denervation
and relaxation of blood vessels, known n Increase success rate
as sympathetic vasomotion. n Can screen for blood
pressure-related fainting
The sympathetic nervous system n non-invasive
controls the body’s automated hemodynamic
functions such as digestion, heart rate monitoring
and the vasomotion of blood vessels.
Disruption of the sympathetic nervous INVENTORS
n Irving Zucker, Ph.D.
system can contribute to a variety of
n Alicia Schiller
chronic diseases, including high blood n Peter Pellegrino
pressure.
One potentially effective way to treat high blood pressure is to

destroy, or ablate, all or parts of the sympathetic nerves of the
kidneys. The problem, however, is until now there has not been
an accurate tool that helps clinicians in real-time determine if the
procedure is targeting the proper areas of the kidneys.
UNMC’s detection system non-invasively monitors sympathetic

nerve activity in real time and determines if a renal denervation
procedure was successful. This technology will help significantly
increase the success rate of renal denervation procedures.
UNMC researchers have shown that the sympathetic vasomotion

detection system can accurately detect renal denervation in rat
and rabbit models. A current study in pigs is expected to further
validate the system’s ability and accuracy.
The sympathetic vasomotion detection system is a versatile tool

that can also monitor and detect other diseases or conditions
associated with the sympathetic nervous system.
In addition to their work with renal denervation, UNMC researchers

are also investigating the device’s use as a screening tool for
blood pressure-related fainting and non-invasive hemodynamic
monitoring.
Contact:
Matt Boehm
mboehm@unmc.edu
402-559-2166

66 TECHNOLOGY
2020
Automated REBOA
New device to save patients
Medical Devices
from catastrophic bleeding
A new automated bleeding-control system that can reduce deaths
related to catastrophic internal bleeding has been developed at the
University of Nebraska Medical Center.
Internal bleeding is a common

result of injuries from car Automated hemorrhage
crashes, falls, and gunshot
wounds, accounting more than control system
half of all American deaths n Rapid occlusion and cessation of
between 1- and 44-years-old. hemorrhaging vessels
Depending on the severity of n Shunts blood flow to down-
the injury, the risk of death stream organs and tissue
increases if the internal bleeding n Reduced mortality from traumat-
is not controlled in the first hour ic bleeding injuries
after the incident. n Easy retrieval of a temporary
endovascular medical device
In the hospital, surgeons n Better and safer alternative for
REBOA
can stop severe bleeding by
n Automated system for reduced
inserting a small balloon into a operator error
blood vessel near the injury site.
The balloon—called a REBOA INVENTORS
or Resuscitative Endovascular n Jason MacTaggart, M.D.
Balloon Occlusion of the Aorta n Alexey Kamenskiy, Ph.D.
device—is then inflated blocking
flow and preventing further blood loss.
The problem with this approach is that traditional REBOA devices

block all blood flow, which can lead to permanent damage if organs
and tissue downstream of the device are starved from their blood
supply for too long. UNMC’s novel device does more than just
block flow: The innovative design has the ability to bypass the
damaged area and maintain blood supply to vital organs and tissues
downstream of the injury.
The automated REBOA device precisely controls inflation and

regulates the amount of blood flow to downstream tissue. The device
is fully automated to decrease user error. It can be easily deployed
within the injured vessel to prevent blood loss at the site of the injury
while preserving blood flow to downstream organs and tissue.
Contact:
Matt Boehm
mboehm@unmc.edu
402-559-2166
TECHNOLOGY
67
2020
Boedeker suction catheter
Medical Devices
Manage the airway of trauma patients
When emergency
staff are challenged
with a trauma patient
that needs to be
intubated, they must
act swiftly. If the
patient suffers from
abundant bleeding of
the mouth, aspiration,
or vomiting the
airway view could be
obstructed.
While standard tubes

are used for suction,
specialized suction may also be necessary. In addition, for a patient
needing intubation, it may also be worthwhile to blow oxygen.
Dr. Ben Boedeker of the University of Nebraska Medical Center has

created a solution to the above mentioned problems.
The Boedeker Suction Catheter is unique as it can be customized

to fit any manufacturer’s blade, it integrates into the blade channel
to keep it out of the way, and it does not only provide suction but
can also blow oxygen to aid in managing the airway. The medical
practitioner utilizing the device can also control the rate of flow or
suction.
In addition, 100% of anesthesiologists who surveyed the device

stated they would like access to the technology. They would also be
very likely to use the device if they had it in their repertoire.
Moreover, according to Emergency Medical Services magazine

(EMS World), the Boedeker Suction Catheter is one of twenty most
innovative products in the field of 2015.
The Boedeker Suction Catheter is currently produced by Truer

Medical. Please contact Dr. Caronda Moore today to find out how
to include this award-winning device to your airway management
products.
Contact:
Joe Runge
hrunge@unmc.edu
402-559-1181
68 TECHNOLOGY
2020
Enhance nanofiber mat properties

Better bandages make better
Medical Devices
scaffolds for repairing tissue
A new technique developed at the University of Nebraska Medical
Center creates better nanofiber mats that could impact a wide
range of health care applications, and could even improve elements
of the environmental, energy, defense and security industries.
In the healthcare industry, better nanofiber mats would make

more absorptive bandages and wound dressings; more effective
scaffolds for tissue engineering and repair; and more efficient
drug delivery materials. More broadly, the technique could also be
used to make better filters, and chemical and biological detection
sensors.
The new method enhances the properties of nanofiber mats

produced by a technique
known as “electrospinning.”
Method increases 3rd dimension
Electrospinning produces
nanometer-sized fibers that, n Increases porosity
in medical applications, are n Creates more absorptive materials
arranged and layered into n Maintains nanoscale surface features
bandage-sized mats. The n Allows for robust cellular infiltration
nanofiber mats can then be and proliferation in nanofiber mats
used as wound dressings
and scaffolds for tissue INVENTORS
regeneration and cell- n Jingwei Xie, Ph.D.
growth. n Jiang Jiang, Ph.D.
Traditional electrospinning typically produces uncontrolled and

densely packed fibers resulting in compact and thin nanofiber
mats. Tightly packed fibers have limited use because they tend to
prevent cells from migrating and growing.
UNMC researchers developed the solution with a new method that

expands electrospun nanofiber mats in the third dimension. The
result is a thicker and deeper mesh that more resembles a sponge.
The method uses a modified gas-foaming technique that essentially

enhances the thickness of the nanofiber mats. The resulting mats
are significantly more porous, making them more absorbent than
traditional nanofiber membranes. Preliminary studies demonstrate
robust cellular infiltration and proliferation within the expanded
nanofiber mats compared to the limited number of cells that are
seen on the surface of traditional nanofiber mats.
Contact:
Matt Boehm
mboehm@unmc.edu
402-559-2166
TECHNOLOGY
69
2020
Synthetic bypass graft
Medical Devices
New design improves bypass
success in lower extremities
of Nebraska Medical Center
developed a highly flexible
vascular bypass graft for the
treatment of peripheral artery
disease.
Peripheral artery disease is a

common circulatory condition
for the elderly, with more
than 3 million new cases per
year. As the body ages, the
vessels carrying vital oxygen
and nutrients throughout the
bloodstream begin to weaken
and narrow, reducing blood flow kinking during normal limb use.
to the limbs. Grafts placed over major joints
like knees and elbows have
To reinforce the vessels, and particularly high fail rates.
support improved blood flow,
physicians can surgically A team of researchers at
implant grafts that protect UNMC, led by vascular surgeon
the vessel integrity. However, Jason MacTaggart, M.D.,
traditional grafts tend to be rigid developed a synthetic graft
and risk severe bending and material that is more flexible
and prevents severe bending
and kinking during normal
Rundown limb use. Their tests indicate
n reinforces vessels, supports that such a graft may improve
improved blood flow blood flow patterns and reduce
n more flexible, prevents severe vascular torsion in patients with
bending and kinking peripheral artery disease.
n ideal for use in major joints like
knees, elbows This new graft design may
INVENTORS improve options for patients
n Jason MacTaggart suffering from peripheral artery
n Kaspars Maleckis disease and offer a higher
quality of life.
Contact:
Matt Boehm
mboehm@unmc.edu
402-559-2166

70 TECHNOLOGY
2020
Airway management, stabilization

Increase a patient’s chance to survive
Medical Devices
with hands-off airway management
An open and clear airway doesn’t always guarantee survival,
but it does increase a patient’s chance to survive. Prioritizing a
compromised airway is always a priority for first-responders. But
when a paramedic’s or EMT’s hands are full keeping the airway
open and clear, the patient’s safety might be at risk as other injuries
go unnoticed.
An innovative emergency medicine team at the University of

Nebraska Medical Center developed a hands-free solution that
requires minimal training. The device grants first-responders the
ability to keep airways open and clear of obstructions. At the same
time, first-responders will be freed to focus on other critical actions,
such as bleeding control, patient stabilization and evacuation.
During primary triage, a compromised airway can be kept open

using the head-tilt, chin-lift technique or the jaw-thrust maneuver—
both of which must be performed continuously, require both hands,
and risk a spinal injury if not done correctly.
An excellent alternative is to establish a quick advanced airway by

inserting an artificial airway in the patient’s mouth. However, this
isn’t always an option as primary responders don’t have the luxury
or tools necessary to establish an advanced airway before having
to rush out and evacuate the scene.
UNMC’s hands-free airway management and stabilization device,

or HAMS, is designed to help rescuers perform the jaw-thrust
maneuver with the flick of a wrist while minimizing the need to
manipulate the patient’s neck. The innovative oral airway device
also includes a device retention slot for hands-free suction or
oxygen administration.
In a mass casualty scenario, this portable device will allow primary

responders to improve and double their efforts by managing the
airways of multiple patients at the same time.
An open and clear airway doesn’t always guarantee survival but it

does increase a patient’s chance to survive. UNeMed is seeking
a partner to complete preclinical testing and help place hands-
free airway management devices with first-responders across the
nation.
Contact:
402-559-3265
TECHNOLOGY
71
2020
Tongue retractor
Intubating made easier
Medical Devices
Airway intubation, the
procedure where an inserted Rundown
n Inexpensive device specialized for
tube assists a patient to clearing the mouth and opening
breathe, can be complicated the jaw
by the patient’s anatomy, n Easy to manufacture as a durable
lack of mobility in the neck, or disposable device
and trauma in the mouth and n A perfect complement to camera
throat. assisted intubation
UNMC physician Ben INVENTORS

Boedeker developed a n Ben Boedeker, M.D., Ph.D.
novel tongue retractor with
a wider working blade and
a more ergonomic curve that helps manage complications during
intubation by immobilizing the tongue and facilitating jaw opening.
The intubating tongue retractor is a proven tool to help manage the

difficult airway. It fills a recognized gap in airway management and
will be an essential tool for any intubation kit.
Contact:
Joe Runge
hrunge@unmc.edu
402-559-1181
72 TECHNOLOGY
2020
Ventilating push rod

Push endotracheal tubes
Medical Devices
in place the simple way
You can live weeks without eating, days without drinking but you
will die in three minutes if you stop breathing.
In an emergency, if you stop breathing, a doctor will try to help you.

The process of assisting in breathing is called managing airways
and it is a critical part of medicine.
Maintaining or establishing an airway is the job of an

anesthesiologist but is sometimes done by emergency doctors or
even by an emergency medical technician (EMT).
Airway management usually involves the placement of a breathing

tube (also called an endotracheal tube). Airway management
is routine part of general anesthesia during surgery but is also
involved trauma or other emergency situations.
Dr. Boedeker invented a new device that will make placing

endotracheal tubes easier.
One common way to place an endotracheal tube is through a

laryngeal mask airway (also know as an LMA). An LMA can be
placed through a patient’s mouth to create a seal around the
patient’s airway, which protects it from trauma, the patient’s body
fluids or other potential blockages. The LMA is not a preferred way
to maintain the airway, it just protects the airway and facilitates
placement of the endotracheal tube.
Dr. Boedeker’s invention is a rod to push the endotracheal tube

into place. Currently, when placing the endotracheal tube through
the LMA, the patient does not receive any air. The placement of
the endotracheal tube needs to happen quickly or else the patient
could die. Dr. Boedeker’s rod has a channel through the middle and
a specially designed tip to allow air to pass through the rod and
into the endotracheal tube.
The ventilating push rod is a practical solution to a critical problem

– keeping sedated patients breathing. It will make placement of
the endotracheal tube through an LMA much easier and give the
doctors more time
Contact:
Joe Runge
hrunge@unmc.edu
402-559-1181
TECHNOLOGY
73
2020
Nanofiber microspheres
Enhance cell delivery
Medical Devices
for improved healing
University of Nebraska electrospraying and are highly

researchers have designed customizable. Invented and
a new nanofiber-based developed at the University
microsphere can deliver cell of Nebraska, the nanofiber
therapies for wound healing and microspheres can be made
tissue regeneration. in a wide variety of shapes
and designs, including hollow
The nanofiber microspheres spheres and spheres with
are manufactured using various sized pores. The
nanofiber microspheres have a
large surface-area-to-volume
Rundown ratio, which helps cellular
n Novel method of microsphere infiltration from the surface into
formation via electrospinning the microsphere.
and electrospraying
n Delivery of cell therapies for
The nanofiber microspheres
wound healing
n Noninvasive alternative to sur- also allow for improved viability
gical scaffold placement and maintenance of stem
cells, making the microspheres
INVENTOR an ideal tool for cell therapy
n Jingwei Xie approaches.
Contact:
Matt Boehm
mboehm@unmc.edu
402-559-2166
74 TECHNOLOGY
2020
Nanofiber rings
Implant, customize drug delivery device
Medical Devices
of Nebraska Medical
Center have developed
a new implantable drug
delivery device made out of
nanofibers.
This new device is a

nanofiber-based ring that is
biodegradable, versatile and
customizable.
The nanofiber rings can

be loaded with a variety
of different types of drugs
including small molecules
and biologics. The devices can
also be loaded with multiple
drugs at one time, allowing for Rundown
the delivery of a combination n Capable of delivering, variety of
therapy. drugs, including small molecules
and biologics
Another unique property of this n Biodegradable
device is that the nanofiber n Can be loaded with more than
rings can be customized to one drug at a time
n Release kinetics of each drug
allow for different release
can be tailored
properties of each drug loaded
into the ring. This includes INVENTOR
delayed release of drugs, n Jingwei Xie, Ph.D.
sequential release of multiple
drugs, and parallel release of
multiple drugs.
The unique properties of the nanofiber ring structure make it ideal

for use as an implantable drug delivery device.
Contact:
Matt Boehm
mboehm@unmc.edu
402-559-2166

TECHNOLOGY
75
2020
Improve AV fistulas
Fistulas mature faster, better & safer
Medical Devices
Healthcare providers now have a better, more reliable way to
improve dialysis in patients with kidney failure.
Hemodialysis simulates kidneys function by filtering a patient’s

blood outside the body to cleanse it from toxins. For dialysis to work
properly, dialysis machines must filter as much blood as possible
during each treatment.
An arteriovenous or AV fistula
is a point of entry and exit to Rundown
the blood vessels that also n First major improvement for the
allows large amounts of blood AV fistula in more than 40 years
to flow uninterrupted. This n Medical device that promotes
portal serves as a connection fistula maturation
between an artery and a vein in n Capable of maturing AV fistulas
the patient’s arm and allows the in an animal model
n Inexpensive, single use
vein to grow large and strong n Multiple applications beyond
providing reliable access to fistula maturation
blood vessels each time.
INVENTOR
AV fistulas are a complex and n Marius Florescu, M.D.
imperfect solution, even when
performed by an expert team of
surgeons and support staff.
The problem with creating AV fistulas is that they require weeks to

months to develop, or mature, and strengthen before a patient can
undergo hemodialysis. Many patients undergoing dialysis are never
able to mature a large fistula.
A better, more reliable way to create AV fistulas seems like a good

idea.
UNMC surgeon, Marius Florescu, M.D. has a new device that

represents the first major improvement for the AV fistula in more
than 40 years. His device promotes better AV fistula creation and
maturation for hemodyalisis.
Dr. Florescu also made a critical discovery during his proof-of-

concept work: Identifying the first known animal model in which AV
fistulas can mature.
Contact:
Joe Runge
hrunge@unmc.edu
402-559-1181
76 TECHNOLOGY
2020
Surgical jet for aortic dissection

Eliminate risks associated
Medical Devices
with open-heart surgeries
AquaBlade, a new
medical device
invented at the
Medical Center,
could provide a less
invasive treatment
for cardiovascular
disease and eliminate
a significant amount
of the inherent risks
associated with open-
heart surgeries.
AquaBlade is an
innovative surgical
instrument that uses a catheter to deliver a specialized cutting tool
through a patient’s artery where it uses a high-pressure water jet to
repair life-threatening tears in artery walls. The device could also be
used to deploy custom-length stents in blood vessels or even help
remove previously deployed stents.
Arterial tears in the inner lining of an artery causes the formation of

blood clots that obstruct blood flow and eventually lead to a heart
attack or stroke. If left untreated, an
arterial tear is fatal for 80 percent
Rundown of patients. Current treatments for
n Treats aortic dissection arterial tears often require open-
n Removes stents heart surgery, which carries a
n Less invasive 25 percent risk of death and an
n Faster patient recovery extended recovery period.
INVENTORS AquaBlade eliminates most of those
n Jason MacTaggart, M.D. risks while also minimizing the
n Alexey Kamenskiy, Ph.D. time of recovery. It is currently at
n Nicholas Phillips
the conceptual stage, preparing a
n Amy Mantz
functional prototype for preclinical
testing.
Contact:
Matt Boehm
mboehm@unmc.edu
402-559-2166
TECHNOLOGY
77
2020
Cardiac vascular access graft
Better care for children with heart defects
Medical Devices
Many babies born with congenital defects of the heart now live to
become adults. Pediatric congenital heart disease and the heart
defects that it produces used to be completely lethal. Surgery for
congenital heart defects can now correct the majority of these
heart defects in infants.
Treatment of heart defects in infants came from tireless innovation

for congenital heart defect surgery and the combined expertise of
teams of medical experts. Pediatric cardiologist Jeffrey Delaney,
M.D., and pediatric thoracic
surgeon James Hammel, M.D.,
embody that innovation. Rundown
n No deviation from current
Dr. Hammel surgically corrects correction of congenital heart
defects
birth defects of the heart and Dr. n Improved access for better
Delaney manages children living management
with congenital defects of the n Easier to use, more efficient
heart. Their collaboration is the
kind of care that has produced INVENTOR
the first generation of adults with n Jeff Delaney, M.D.
congenital heart disease.
Together, they have invented a

new pediatric medical device to correct heart defects. The device,
utilized in the final stages of a Fontan procedure, will help facilitate
management of the patient’s congenital heart defects. A novel
shunt, the device replaces traditional tubes that redirect blood flow
away from defective parts of the hearth.
The improved device has permeable membranes to help the

cardiologist regulate pressure in the tube. A radio opaque
ring wreaths the membrane, making it easy to locate utilizing
radiography.
Doctors Hammel and Delaney are prepared to conduct an animal

study that will further validate the device. Contact UNeMed to
discuss how to bring this vital new device to market and give
children with life threatening heart defects more options in their
care.
Contact:
Joe Runge
hrunge@unmc.edu
402-559-1181
TECHNOLOGY
2020
cancer PORTFOLIO
cardiovascular
drug delivery
infectious diseases
medical devices
metabolic
miscellaneous
neurologic
research tools
software
startups
TECHNOLOGY
79
2020
PORTFOLIO METABOLIC
Type I Diabetes Diagnostic

New blood test may
improve diabetic outcomes
A new method for assessing the
risk of developing Type I diabetes Rundown
could help physicians make n Type I diabetes diagnostic
Metabolic
diagnoses earlier than ever before. n Simple blood test
A simple blood test developed n Helps predict immunotherapy
treatments
at the University of Nebraska n Flow cytometry based assay
Medical Center monitors certain to assess populations of
immune cell populations which T-cell subsets
can indicate changes in normal
physiology. INVENTORS
n Nora Sarvetnick, Ph.D.
This method may catch Type 1 n Robert Harms
diabetes earlier, which would
mean more therapeutic and
preventative options for patients and their physicians. This method
might also predict patient responses to immunological treatment
options.
Current diagnostics of Type 1 diabetes rely on the presence of

circulating antibodies. Those antibodies only become detectable
once the disease has progressed to the point of irreparably
damaging healthy tissue.
Type 1 diabetes occurs when the body’s immune cells target

healthy tissue in the pancreas. The pancreas is responsible for
producing insulin, which is a vital part of how the body processes
sugar in the blood. Once the immune cells destroy the parts of
the pancreas responsible for insulin production, sugar is no longer
processed normally, which is why people with Type 1 diabetes
need daily insulin injections to survive.
Contact:
Matt Boehm
mboehm@unmc.edu
402-559-2166

80 TECHNOLOGY
2020
METABOLIC PORTFOLIO
Improve AV fistulas
Fistulas mature faster, better & safer
Healthcare providers now have a better, more reliable way to
improve dialysis in patients with kidney failure.
Hemodialysis simulates kidneys function by filtering a patient’s

blood outside the body to cleanse it from toxins. For dialysis to work
Metabolic
properly, dialysis machines must filter as much blood as possible
during each treatment.
An arteriovenous or AV fistula
is a point of entry and exit to Rundown
the blood vessels that also n First major improvement for the
allows large amounts of blood AV fistula in more than 40 years
to flow uninterrupted. This n Medical device that promotes
portal serves as a connection fistula maturation
between an artery and a vein in n Capable of maturing AV fistulas
the patient’s arm and allows the in an animal model
n Inexpensive, single use
vein to grow large and strong n Multiple applications beyond
providing reliable access to fistula maturation
blood vessels each time.
INVENTOR
AV fistulas are a complex and n Marius Florescu, M.D.
imperfect solution, even when
performed by an expert team of
surgeons and support staff.
The problem with creating AV fistulas is that they require weeks to

months to develop, or mature, and strengthen before a patient can
undergo hemodialysis. Many patients undergoing dialysis are never
able to mature a large fistula.
A better, more reliable way to create AV fistulas seems like a good

idea.
UNMC surgeon, Marius Florescu, M.D. has a new device that

represents the first major improvement for the AV fistula in more
than 40 years. His device promotes better AV fistula creation and
maturation for hemodyalisis.
Dr. Florescu also made a critical discovery during his proof-of-

concept work: Identifying the first known animal model in which AV
fistulas can mature.
Contact:
Joe Runge
hrunge@unmc.edu
402-559-1181
TECHNOLOGY
2020
cancer PORTFOLIO
cardiovascular
drug delivery
infectious diseases
medical devices
metabolic
miscellaneous
neurologic
research tools
software
startups
82 TECHNOLOGY
2020
MISCELLANEOUS PORTFOLIO
Modular prosthetic arm

Prosthetics adapts to lifestyle
Miscellaneous
A modular prosthetic arm, invented at UNO Biomechanics, is body-
powered, lightweight and made to accommodate a smorgasbord
of task-specific end-effector attachments. The end-effectors are
specially engineered to perform specific, challenging tasks such
as playing a stringed instrument, swimming, riding a bike, and
participating in team sports like basketball and baseball.
The end-effectors can be easily removed and replaced as needed

so active users can easily move from one task to the next.
Brendan Sullivan/Omaha World-Herald

Lincoln fourth-grader Peyton Tiernan can now play the cello with a pros-
thesis design by a UNO team — am arm with a clamp on the end that locks
onto the bow.
Read the full article at: https://www.omaha.com/livewellnebraska/
inspiration/lincoln-boy-learns-cello-with-help-from-a-uno-designed/
article_5baf4226-d347-5e6e-a95b-ae1273b6a3a3.html
Contact:
Tyler Scherr
402-559-2140

TECHNOLOGY
83
2020
PORTFOLIO MISCELLANEOUS
Nanofiber microspheres
Enhance cell delivery
Miscellaneous
for improved healing
University of Nebraska electrospraying and are highly

researchers have designed customizable. Invented and
a new nanofiber-based developed at the University
microsphere can deliver cell of Nebraska, the nanofiber
therapies for wound healing and microspheres can be made
tissue regeneration. in a wide variety of shapes
and designs, including hollow
The nanofiber microspheres spheres and spheres with
are manufactured using various sized pores. The
nanofiber microspheres have a
large surface-area-to-volume
Rundown ratio, which helps cellular
n Novel method of microsphere infiltration from the surface into
formation via electrospinning the microsphere.
and electrospraying
n Delivery of cell therapies for
The nanofiber microspheres
wound healing
n Noninvasive alternative to sur- also allow for improved viability
gical scaffold placement and maintenance of stem
cells, making the microspheres
INVENTOR an ideal tool for cell therapy
n Jingwei Xie approaches.
Contact:
Matt Boehm
mboehm@unmc.edu
402-559-2166
84 TECHNOLOGY
2020
Transesophageal Echocardiography Phantom

Modular TEE simulator
provides lifelike training
Miscellaneous
Nick Markin, M.D., Director of
Perioperative Imaging at the University Rundown
of Nebraska Medical Center, n Acquire, manipulate
invented a modular Transesophageal 3D color flow Doppler
Echocardiography (TEE) Phantom. images
The TEE Phantom allows the user n Modular design enables
to acquire and manipulate 3D color practice with multiple
flow Doppler images of multiple heart heart abnormalities
abnormalities while using a clinical n Connects to clinical echo
echo machine. machines
n Lifelike training experi-
ence
TEE is a powerful technology for
diagnosing heart disease and INVENTOR
monitoring the heart condition during n Nick Markin, M.D.
surgery. However, the procedure can
be tricky and current educational
simulators are expensive, limited, or do not use an actual clinical
echo machine. This technology would provide crucial training for
medical students and residents on the actual clinical machine prior
to performing the procedure on a real patient.
Contact:
Tyler Scherr
402-559-2140
TECHNOLOGY
85
2020
Custom Medical Simulators

Lifelike models provide
Miscellaneous
doctors just-in-time training
Nick Markin, M.D., Director of
Perioperative Imaging at the University Rundown
of Nebraska Medical Center, invented n Anatomically accurate
custom medical procedures simulators. n Layered models: arti-
These anatomically accurate simulators ficial bone, tissue and
are made with artificial mimics of vasculature
n Echogenic
bone, tissue and vasculature. They n Critical vascular and
are echogenic and provide training for non-vascular access
multiple critical vascular access and procedures
non-vascular access procedures when
they are needed most. INVENTOR
n Nick Markin, M.D.
Anesthesiologists perform many
routine procedures, but occasionally
receive patients with extreme trauma that require immediate and
unique assistance. Due to the rarity of these events, it is difficult
for clinicians to receive this crucial training. To solve this training
gap, Dr. Markin developed a process for creating custom medical
procedure simulators that fit into the “just-in-time” educational
model. A “just-in-time” training platform is one that provides
educational tools and courses as they are needed, rather than
waiting for online courses or sporadic seminars.
Dr. Markin’s portfolio currently contains intraosseous infusion

and arterial cannulation models, with several more simulators in
development.
Contact:
Tyler Scherr
402-559-2140
86 TECHNOLOGY
2020
WASP: Wearable Apparatus for Slip Perturbations

Produce natural, unpredictable
Miscellaneous
slipping experiences in the lab
Slips and falls are
random, but preventing
them is an act of
bottled chaos. How do
you intentionally cause
someone to fall by
accident? Now, leading
human gait researcher,
Nathaniel Hunt,
Ph.D., and his team
in the biomechanics
department at the
at Omaha invented
a device that induces a truly natural and unpredictable slipping
experience.
The Wearable Apparatus for Slip

Perturbations, or WASP for short, Rundown
easily attaches to a subject’s shoe n Natural slipping experi-
and produces rapid loss of foot-to- ence
n Unpredictable slipping
ground friction. It can be wirelessly
experience
controlled by the researcher, n Wireless controllability
enabling the observation of slipping n Potential applications in
throughout the entire gait cycle. research and clinic
It is also unpredictable, allowing
researchers to isolate and remove INVENTORS
anticipatory responses from the n Kyle Brozekn
reactive responses of interest. n Nathaniel Hunt
n Corbin Rasmussen
This device has tremendous n Andrew Walski
potential in biomechanics research
as well as clinical applications in fall
prevention training.
Contact:
Tyler Scherr
402-559-2140
TECHNOLOGY
87
2020
Self-Pacing treadmill
New treadmill adjusts to user’s pace
Miscellaneous
For the first time, a self-pacing
treadmill can now speed up and slow Rundown
down to match the pace of its user, n Dramatically improves
thanks to a team of scientists at the treadmill safety
University of Nebraska at Omaha. n Better simulates outdoor
running
The technological breakthrough n Requires only software
not only opens up a whole new and inexpensive sensors
range of opportunities in recovery
INVENTORS
and rehabilitation, but eliminates n Casey Wiens, Ph.D.
the danger of current treadmills n Molly Schieber, Ph.D.
throwing runners who misstep or fail n William Denton, Ph.D.
to keep pace. Some 24,000 go to
the emergency room each year with
treadmill related injuries.
The UNO team combined some sensors with a complex,

biomechanical analysis of the runner’s gait to build a treadmill that
starts and stops when the user does—and all points between,
whether that’s slowing from a jog to a walk, or speeds from a walk
to a sprint. The user maintains total control of the pace, without any
need to interact with a console.
Contact:
Joe Runge
hrunge@unmc.edu
402-559-1181

88 TECHNOLOGY
2020
Lab safety posters

Let students see
themselves in the laboratory
Miscellaneous
Scientific observations
are just like any
other: informed by a
person’s upbringing,
biases and likes. The
key to good science
is diverse scientists
so those observations
are made from many
points of view.
Science education
needs to reach
out to everyone. Science, Technology, Engineering and Math,
STEM education, needs to do more to make scientists, engineers
and mathematicians as diverse as the people that rely on their
discoveries. Maurice Godfrey, Ph.D., produced science classroom
posters that promote laboratory safety rules. The classroom
posters depict students from diverse ethnic backgrounds. Each
one focuses on a different aspect of laboratory safety.
Dr. Godfrey produced

Rundown the stem posters to
n Fun posters promote laboratory safety include with teacher
n Available for purchase through Amazon resources in mobile
science classrooms
INVENTORS
n Maurice Godfrey, Ph.D. to educate Native
n Kim Soper American children.
n Liliana Bronner These innovative
n Tracy Arobba posters are now
n Roxanna Jokela available to the public
n Eric Haas through Nebraska
Scientific.
Contact:
Jason Nickla
jnickla@unmc.edu
402-559-8983
TECHNOLOGY
89
2020
PDE4B selective inhibitors
Improve treatments for
inflammatory diseases
Miscellaneous
A UNMC chemist has developed
new compounds for the treatment of Rundown
inflammatory diseases. n Selective for the B
isoform of PDE4
These compounds target a protein n Enhanced uptake into
called phosphodiesterase 4, or the CNS
PDE4 for short. PDE4 regulates n Nanomolar potency
inflammation, and is involved in a n Useful for treating a
number of inflammatory diseases such variety of inflammatory
diseases
as chronic obstructive pulmonary
disease, rheumatoid arthritis, psoriasis, INVENTOR
atopic dermatitis, inflammatory bowel n Corey Hopkins, Ph.D.
disease, and central nervous system
diseases that include drug addiction,
schizophrenia and neurodegenerative
diseases.
Several approved drugs currently target PDE4, but with severe side
effects—like nausea and vomiting—that limit their use. Many of the
current PDE4 inhibitors have poor uptake into the central nervous
system which limits their use in the treatment of central nervous
system diseases.
UNMC’s new PDE4 inhibitors target a specific isoform of PDE4, the

B isoform. Targeting PDE4B should help significantly reduce side
effects such as nausea and vomiting.
The new PDE4 inhibitors are designed for increased uptake into
the central nervous system, making them more useful than current
drugs for treating central nervous system-related inflammatory
diseases.
Initial lead compounds exhibit nanomolar potency against PDE4B,

an 8-10 fold improved selectivity for PDE4B, and good uptake
into the brain. One lead compound has also shown significant
improvement in a mouse model of cocaine addiction.
Contact:
Matt Boehm
mboehm@unmc.edu
402-559-2166
90 TECHNOLOGY
2020
Hybrid arm
One device combines best of body-
powered, motor-driven prostheses
Miscellaneous
A new cyborg
prosthetic arm design
brings prosthetics
one step closer to
replicating anatomy.
Traditional
electronically-powered
prostheses have two
common downfalls:
weight and a lack of
manual, body-powered
control.
To solve these issues, a research team at UNO Biomechanics

designed a novel prosthetic arm that incorporates the best of
both worlds: It has both the lightweight feel of a body-powered
prosthetic and the improved functionality of an electronically-
powered device.
Using a body-powered prosthetic base, the hybrid arm still

provides manual control.
Manual motor control is an important feature because it permits the

development of healthy and strong muscles in children who would
normally abandon the use of their affected limb. That leads to long-
term weakness and even postural
problems such as scoliosis. Rundown
n Strategically combines
To reduce weight and enhance ease body-powered and motor-
of use, fewer (and lighter-weight) driven actuation
motors are used. n Lightweight
n Ergonomic
Rather than developing all of the n Decreased muscle fatigue
force needed to grip objects, INVENTORS
the motors in this hybrid design n James Pierce
are intended to augment the n Jean Peck
user’s strength to make using the n Jorge Zuniga, Ph.D.
prosthetic easier and to encourage n Rakesh Srivastava
them to use the strength they have. n Walker Arce
Contact:
Tyler Scherr
402-559-2140

TECHNOLOGY
2020
cancer PORTFOLIO
cardiovascular
drug delivery
infectious diseases
medical devices
metabolic
miscellaneous
neurologic
research tools
software
startups
92 TECHNOLOGY
2020
NEUROLOGIC PORTFOLIO
Parkinson’s Disease
New method allows for early diagnosis
A new discovery at the
Medical Center could take
most of the guesswork out
of delivering an accurate
Neurologic
and reliable diagnosis for
Parkinson’s disease.
Current methods for

diagnosing the more
than 1 million Americans
suffering from Parkinson’s
involve a basic
neurological exam and
information provided by
the patient. The resulting diagnosis in early stage patients is often
inaccurate, inconsistent, and must be periodically reevaluated.
A team led by research physician Howard Gendelman—the 2008

Scientist Laureate, UNMC’s highest research honor—discovered
a unique correlation between Parkinson’s disease and a protein
found in a certain subset of immune cells called T-cells. An
abundance of the protein could
indicate a more severe case of
Rundown the disease.
n Parkinson’s Diagnostic
n Uses patient’s cells Researchers are currently
n Correlates immune cells with developing a simple blood
disease test that could help physicians
n May allow for earlier and more detect and monitor the disease
accurate diagnosis at the earliest stages. Early
n Can monitor disease progression
and therapy
testing indicates a blood
screen using this method
INVENTORS would help patients and their
n Howard Gendelman, M.D. doctors diagnose, track and
n R. Lee Mosley, Ph.D. monitor Parkinson’s disease
n Jessica Hutter Saunders, Ph.D. with more accuracy and
confidence than ever before.
Contact:
Matt Boehm
mboehm@unmc.edu
402-559-2166
TECHNOLOGY
93
2020
PORTFOLIO NEUROLOGIC
Parkinson’s Disease
Vaccine may signal beginning
of end to Parkinson’s disease
A novel combination developed by researchers at the University
of Nebraska Medical Center may be the final solution that could
Neurologic
deliver a knockout blow to Parkinson’s disease.
Howard Gendleman, M.D.,

and his team believe they are Rundown
on the verge of producing an n Novel therapeutic combination
n Treats underlying factors, not
effective vaccine to battle the
just symptoms
debilitating disorder that affects n Treats existing disease
more than 1 million Americans. n Prevents future disease
Right now, the only treatment n Potentially useful for other neu-
options for Parkinson’s— rodegenerative disorders
the world’s second-leading
neurodegenerative disorder INVENOTRS
behind Alzheimer’s—are n Howard Gendelman, M.D.
methods for reducing symptoms. n R. Lee Mosley, Ph.D.
n Ashley Reynolds, M.D., Ph.D.
But if Gendleman’s approach
succeeds, the immune systems
of vaccinated patients will be armed to fend off the disease and
prevent its disastrous effects.
The vaccine turns an old foe into a potential ally.
Vaccination with a protein, alpha-synuclein, alone actually has the

ability to make Parkinson’s even worse. But when the protein is
paired with an immune modulator, it promotes an immune response
that protects brain cells from further damage.
Preclinical studies show a remarkable 91 percent survival rate

of neurons in treated laboratory mice. In January 2014, early
stage clinical trial testing began on one of the vaccine’s critical
components. The early test will help determine if the immune
system of a Parkinson’s patient can be successfully modulated.
Contact:
Matt Boehm
mboehm@unmc.edu
402-559-2166
TECHNOLOGY
2020
cancer PORTFOLIO
cardiovascular
drug delivery
infectious diseases
medical devices
metabolic
miscellaneous
neurologic
research tools
software
startups
TECHNOLOGY
95
2020
PORTFOLIO RESEARCH TOOLS
COVID-19
GEMs for COVID-19
Find answers with genetically
Research Tools
engineered mice for SARS-CoV-2
Mouse models could create opportunity for creating a
answers to several lingering versatile set of genetically
unanswered questions about engineered mouse models
the COVID-19 outbreak and the useful for COVID-19 and SARS-
virus that created it, SARS- CoV-2 research.
CoV-2. Geneneticlly engineered
mice will help scientists UNMC researcher,
understand the molecular Channabasaviah Gurumurthy,
mechanisms of the virus, PhD, has developed three
repurpose currently available broad categories of genetically
antiviral drugs, and provide an engineered mouse models,
opportunity to develop new and about 30 different model
therapies and vaccines against designs for SARS-CoV-2
COVID-19. One major challenge research:
in achieving these goals is 1. Knocking-in expression
the lack of suitable preclinical cassettes, or point
animal models. mutations, into the
endogenous mouse ACE2
Unfortunately, SARS-CoV-2 locus.
only infects mice if they express 2. Knocking-in CRE-
human ACE2. This feature, activatable- or tetracycline
combined with a wealth of inducible-hACE2
genetic tools available only expression cassettes into
in mice, offers a unique safe-harbor loci, by re-
engineering the existing
reporter or inducer lines.
Rundown 3. Knocking-in CRE-
n Preclinical mouse models activatable cassettes into
directed towards a variety of the mouse ACE2 locus.
members in the SARS-CoV-2
transmission process The natural non-permissiveness
n Models are generated under
of mice to SARS-CoV-2
different mouse backgrounds
n Research use only infection in combination with a
wide variety of available genetic
INVENTORS tools and molecular switches
n Channabasavaiah Gurumurthy offers a unique opportunity to
n Masato Ohtsukan make this species useful for
n Rolen Quadros COVID-19 research.
Contact:
402-559-3265
96 TECHNOLOGY
2020
RESEARCH TOOLS PORTFOLIO
Alcohol dehydrogenase-expressing VA-13 cells

Cell line available for the
Research Tools
study of ethanol metabolism
Alcoholic liver disease (ALD) is a major problem associated
with alcohol abuse. In fact, ALD is the second leading cause of
death among all liver diseases. It is believed that ALD is due to a
decreased ability of hepatocytes to regenerate due to prolonged
exposure to toxic metabolic byproducts produced during alcohol
oxidation/metabolism.
One of the key enzymes

involved in alcohol oxidation Rundown
is alcohol dehydrogenase n Research use only
(ADH). ADH converts ethanol n Non-exclusive licenses available
to acetaldehyde, which can
then be converted to acetate INVENTOR
n Dahn L Clemens, Ph.D.
by aldehyde dehydrogenase.
Production of acetaldehyde
from ethanol generates
reactive oxygen species which in turn cause oxidative stress that
can eventually lead to the development of ALD. However there is
currently a great deal that is unknown about the exact mechanisms
leading to the development of ALD.
To help study the metabolic basis of ethanol-induced hepatocellular

injury researchers at the University of Nebraska Medical center
have created a cell line using human hepatocellular carcinoma
(HepG2) cells stably expressing ADH (VA-13 cells).
They have shown that VA-13 cells metabolize ethanol into

acetaldehyde and have a dramatic increase in the NADH/NAD+
ratio indicating an increased redox-state. VA-13 cells cultured
in the presence of ethanol also have a significant reduction in
cell accumulation due to increased cytotoxicity and impaired
DNA synthesis compared to cells without ADH. Further studies
determined that the impairment of cell cycle progression in VA-13
cells was due in part to decreased Cdc2 activity.
This cell line is a promising tool that will help further elucidate the
mechanisms of ethanol-induced hepatocellular injury.
Contact:
Matt Boehm
mboehm@unmc.edu
402-559-2166
TECHNOLOGY
97
2020
iGONAD: improved-Genome editing
Research Tools
via Oviductal Nucleic Acids Delivery
Directly edit zygote genes
The i-GONAD method delivers – requiring a high level of
genome editing molecules, expertise, expensive and time-
directly to E0.7 embryos in consuming.
the oviducts of mice, via in
situ electroporation. This The i-GONAD technique relives
technique generates mouse these steps by delivering
models that can contain single genome editing nucleic acids
base changes, kilobase sized and CRISPR components into
deletions and knock-ins. embryos in situ. The process
i-GONAD treated females retain involves the exposure of the
reproductive function and are ovaries and oviduct of pregnant
useful for generating germlines mice bearing E0.7 embryos.
in future generations. The genome editing reagents
are injected into the oviductal
The University of Nebraska lumen and the entire oviduct
Medical Center’s is subjected to electroporation
Channabasavaiah Gurumurthy, using tweezer-type electrodes.
Ph.D., collaborated with These in situ, genome edited
Japanese researchers embryos are allowed to develop
Masato Ohtsuka, Ph.D., to term and genotyped for the
and Hiromi Miura, Ph.D., of targeted mutation.
Tokai University’s School of
Medicine, invented i-GONAD This technique, when used in
. Traditionally, generating combination with Easi-CRISPR,
transgenic mouse-models another invention from Dr.
involves three critical steps: Gurumurthy and Dr. Ohtsuka,
isolation of zygotes from inserts long single stranded
sacrificed females, zygote DNA donor format with insertion
micromanipulation ex vivo efficiency as high as 100%.
and transfer of these modified This combination changes the
zygotes into another set of landscape of transgenic animal-
female mice. This process has model generation and provides
remained unchanged for over a tool that is easy-to-perform
four decades and is laborious and has high efficiency.
Contact:
402-559-3265

98 TECHNOLOGY
2020
Bio-imaging containment unit

Transport, image specimens while
Research Tools
maintaining biosafety level 3 quarantine
The bio-imaging
containment unit is a
three-in-one isolation,
transportation and
imaging device. This
new invention permits
medical imaging of multiple
specimens in biosafety
level 3 (BSL3) quarantine.
Additional features allow
for anesthesia delivery
and real-time specimen
monitoring.
The bio-imaging containment unit includes a sealed, medical-

grade filtration system entirely comprised of non-ferrous materials.
The unit is portable, specifically designed to fit medical imaging
systems, and scalable to hold living specimens over a wide
range of sizes. The device has multiple, additional features
including anesthesia delivery, real-time specimen monitoring via
communication lines, and a self-contained uninterruptable power
supply.
By facilitating medical imaging,

Rundown such as an MRI, of living
n Effective BSL3 quarantine unit
n Easily transportable specimens in isolation, this
n Facilitates medical imaging technology will accelerate
within unit innovative research and enable
n Anesthesia delivery system world-class imaging facilities
n Real-time specimen moni- to perform immediate data
toring collection on outside specimens.
This unit can also be used to
INVENTORS safely transport and image
n Shea Lundeby, M.D.
immunocompromised specimens.
Contact:
Tyler Scherr
402-559-2140
TECHNOLOGY
99
2020
Rapid co-culture model for atherosclerotic diseases

New way finds better
Research Tools
drugs for heart disease
A team of scientists
at UNMC invented a
milestone between the
petri dish and animal
tests, which could save
the drug development
industry untold millions
in research and
development. Using
a known technique
called co-culture, the
scientists invented a
highly efficient way to
create artificial arteries
that could reduce the Gap junction between the endothelial cells (arrow heads)
cost of drug discovery. were identified under scanning electron microscope.
Monocytes bond to endothelial cells at gap junction area
(white arrows). Monocyte migrated into and underneath the
In the complex and endothelial cell layer (red arrow).
expensive realm of
drug discovery, scientists screen drugs
in a series of increasingly expensive Better drugs for
experiments. One of the earliest jumps in heart disease
expense is going from testing drugs on n Low cost, easy to
cells in a petri dish to testing the drugs in produce co-culture
living animals. Frequently, drugs that work model
in the petri dish eventually fail in animals. n Accurately models
artery physiology
But now, UNMC’s inventors can create n Inexpensively simu-
a simulated artery that models the lates atherosclerotic
disease
progression of coronary artery disease.
The model can test new drugs that slow INVENTORS
or reverse the progression of the leading n Ioannis Chatzizisis,
cause of death in the United States, M.D., Ph.D.
coronary artery disease. n Xiang-De Liu, M.D.
Contact:
Joe Runge
hrunge@unmc.edu
402-559-1181

100 TECHNOLOGY
2020
WASP: Wearable Apparatus for Slip Perturbations

Research Tools
Produce natural, unpredictable
slipping experiences in the lab
Slips and falls are
random, but preventing
them is an act of
bottled chaos. How do
you intentionally cause
someone to fall by
accident? Now, leading
human gait researcher,
Nathaniel Hunt,
Ph.D., and his team
in the biomechanics
department at the
at Omaha invented
a device that induces a truly natural and unpredictable slipping
experience.
The Wearable Apparatus for Slip

Perturbations, or WASP for short, Rundown
easily attaches to a subject’s shoe n Natural slipping experi-
and produces rapid loss of foot-to- ence
n Unpredictable slipping
ground friction. It can be wirelessly
experience
controlled by the researcher, n Wireless controllability
enabling the observation of slipping n Potential applications in
throughout the entire gait cycle. research and clinic
It is also unpredictable, allowing
researchers to isolate and remove INVENTORS
anticipatory responses from the n Kyle Brozekn
reactive responses of interest. n Nathaniel Hunt
n Corbin Rasmussen
This device has tremendous n Andrew Walski
potential in biomechanics research
as well as clinical applications in fall
prevention training.
Contact:
Tyler Scherr
402-559-2140
TECHNOLOGY
101
2020
Abdominal access viewport
Custom viewport reveals
Research Tools
organs, delivers medication
A novel abdominal window enables researchers to view functioning
tissue and organs of living animals. The surgically implanted
device is made from multiple biocompatible materials and highly
customizable.
The Abdominal Access

Viewport offers a new,
affordable and customizable Rundown
method of performing accurate n Surgically implanted above the
observations during long- tissue or organ of interest
term animal studies. With n Provides drug delivery and
real-time imaging
applications in numerous n Can be mounted to a micro-
animal models including scope for precise, longitudinal
surgical intervention, infection, studies
tumor placement, and drug n Highly customizable for different
screening, among others, animals, organs, and micro-
this versatile research scopes
tool upgrades a standard
microscope into a real-time INVENTORS
imaging system. n Ayrianne Crawford, Ph.D.
n Bin Duan, Ph.D.
A rigid window frame n Tony Hollingsworth, Ph.D.
containing a glass coverslip is
surgically implanted onto the
surface of the animal above the
tissue or organ of interest, and can be tailored to allow microscopic
imaging and drug delivery.
This new device provides researchers with two major benefits.

First, the window allows real-time imaging of live-animal tissues
with nearly any laser microscope, which eliminates the need for an
inverted microscope. Second, access portals allow the delivery of
a range of substances, including macromolecules, pharmaceuticals
and cellular populations for real-time monitoring of tissue response.
Contact:
Joe Runge
hrunge@unmc.edu
402-559-1181
102 TECHNOLOGY
2020
Easi-CRISPR
Increase DNA insertion
Research Tools
efficiency with Easi-CRISPR
CRISPR, the newest
gene editing technology,
efficiently slices DNA
unlike any other known
procedure. It’s a scientist’s
dream to delete mutated
or faulty DNA. But CRISPR
solves only half the
problem.
While CRISPR can delete

DNA, the process for
replacing that piece has
been unwieldly, imprecise
and inefficient.
Easi-CRISPR is a simple protocol that inserts long, single-stranded

DNA with remarkably high efficiency rates—up to 100 percent in
some genes.
As a research tool, Easi-

Rundown CRISPR could have
n Highly efficient for animal model a profound impact in
generation developing new genetically
n Insert large single-stranded DNA engineered model
fragments with 83 percent efficiency organisms—including
n Similar efficiency in therapeutic ap-
animals, cells and plants—
plications using electroporation
and other testing media
INVENTORS that could lead to future
n Channabasavaiah Gurumurthy, Ph.D. cures of genetic conditions.
n Masato Ohtsuka, Ph.D. The protocol takes
n Hiromi Miura, Ph.D. approximately two months
to generate either knock-in
or conditional knock-out
mouse models.
Contact:
402-559-3265

TECHNOLOGY
103
2020
Cbl-b conditional knockout mouse

Mouse model available for the
Research Tools
study of autoimmune disorders
Casitas B cell
lymphoma-b (Cbl-b)
is a member of the
mammalian Cbl family
of proteins which are
characterized by an
N-terminal tyrosine
kinase binding domain,
linker domain, RING
finger domain, and a
variable C-terminal
domain. Cbl-b is an E3
ubiquitin ligase that is
critical for the proper
regulation of various
receptor tyrosine
kinases and non-receptor tyrosine kinases.
Loss of function of Cbl-b has been linked to a variety of diseases

including cancer, myeloproliferative disorders, and autoimmune
diseases such as arthritis and type 1 diabetes mellitus.

created a conditional knockout Cbl-b mouse model. This novel
mouse model allows for tissue specific knockdown of Cbl-b, which
will be useful for exploring
the role of Cbl-b in the
Rundown development of autoimmune
n Research use only diseases. These mice will also
n Non-exclusive licenses available
provide a model to assess
INVENTORS the efficacy of new anti-
n Hamid Band, M.D., Ph.D. inflammatory drugs and will
n Vimla Band, Ph.D. be useful for the identification
n Mayumi Naramura of new biomarkers and drug
n Bhopal Mohapatra targets for autoimmune
disorders.
Contact:
Matt Boehm
mboehm@unmc.edu
402-559-2166
104 TECHNOLOGY
2020
Enhance nanofiber mat properties

Better bandages make better
Research Tools
scaffolds for repairing tissue
A new technique developed at the University of Nebraska Medical
Center creates better nanofiber mats that could impact a wide
range of health care applications, and could even improve elements
of the environmental, energy, defense and security industries.
In the healthcare industry, better nanofiber mats would make

more absorptive bandages and wound dressings; more effective
scaffolds for tissue engineering and repair; and more efficient
drug delivery materials. More broadly, the technique could also be
used to make better filters, and chemical and biological detection
sensors.
The new method enhances the properties of nanofiber mats

produced by a technique
known as “electrospinning.”
Method increases 3rd dimension
Electrospinning produces
nanometer-sized fibers that, n Increases porosity
in medical applications, are n Creates more absorptive materials
arranged and layered into n Maintains nanoscale surface features
bandage-sized mats. The n Allows for robust cellular infiltration
nanofiber mats can then be and proliferation in nanofiber mats
used as wound dressings
and scaffolds for tissue INVENTORS
regeneration and cell- n Jingwei Xie, Ph.D.
growth. n Jiang Jiang, Ph.D.
Traditional electrospinning typically produces uncontrolled and

densely packed fibers resulting in compact and thin nanofiber
mats. Tightly packed fibers have limited use because they tend to
prevent cells from migrating and growing.
UNMC researchers developed the solution with a new method that

expands electrospun nanofiber mats in the third dimension. The
result is a thicker and deeper mesh that more resembles a sponge.
The method uses a modified gas-foaming technique that essentially

enhances the thickness of the nanofiber mats. The resulting mats
are significantly more porous, making them more absorbent than
traditional nanofiber membranes. Preliminary studies demonstrate
robust cellular infiltration and proliferation within the expanded
nanofiber mats compared to the limited number of cells that are
seen on the surface of traditional nanofiber mats.
Contact:
Matt Boehm
mboehm@unmc.edu
402-559-2166

TECHNOLOGY
105
2020
Panc02-MUC1 cells
Cell line available for in vivo study of anti-
Research Tools
tumor effects of therapeutic compounds
on MUC1-expressing pancreatic tumors
Pancreatic cancer is one
of the leading causes of
cancer related deaths.
Pancreatic cancer is
seldom detected at an
early stage, spreads
rapidly, and has poor
prognosis with less than
5% surviving over a
five-year time span. The
majority of all patients
with pancreatic cancer
have non-operable
disease and current
chemotherapies and radiotherapies are largely ineffective. As a
result, novel therapies that can effectively target pancreatic cancer
and help prevent metastasis are needed.

developed a mouse pancreatic tumor cell line overexpressing
human MUC1. MUC1 is a protein that is expressed in over 90%
of pancreatic tumors and is aberrantly glycosylated. Thus MUC1
appears to be a potential target for the development of pancreatic
cancer therapies.
Researchers have shown that subcutaneous immunization of

mice with MUC1-overexpressing pancreatic tumor cells, provided
protection against subsequent intra-pancreatic tumor challenge
with MUC1-overexpressing pancreatic tumor cells. Furthermore,
through the use of MUC1-overexpressing pancreatic tumor
cells researchers have discovered a number of specific immune
components required for the elimination of pancreatic tumors
expressing MUC1.
This technology provides an in vitro model for testing and

developing MUC1 targeted pancreatic cancer therapies and for
studying in vivo anti-tumor effects of therapeutic compounds on
MUC1-expressing pancreatic tumors.
Contact:
Matt Boehm
mboehm@unmc.edu
402-559-2166

106 TECHNOLOGY
2020
Prostate cancer cells

Study androgen resistance development
Research Tools
Prostate cancer is
usually treated with
watchful waiting,
surgery, radiation
therapy, chemotherapy,
cryosurgery,
hormonal therapy, or
some combination.
Hormonal therapy
uses medications such
anti-androgens to
block prostate cancer
cells from getting
dihydrotestosterone,
a hormone produced
in the prostate and
required for the growth and spread of most prostate cancer cells.
However use of anti-androgens is limited by rapidly acquired
within few months’ resistance of prostate cancer cells to hormonal
therapy.
Researchers at University of Nebraska Medical Center have

discovered that induced expression of cellular Prostatic Acid
Phosphatase inhibits the tumor resistance to androgen deprivation
therapy, restoring and prolonging therapy effect and observed that
reduced cellular Prostatic Acid Phosphatase expression in cancer
cells leads to prostate cancer progression, which can be used as
a long-term prediction hormonal therapy success and diagnosis of
prostate cancer.
Scientists at UNMC then developed a novel cell line which mimics

the stages of resistance to androgen therapy for study of the
molecular mechanisms by which androgen therapy sensitive
prostate cancer cells differentiate to androgen resistant cancer
cells.
This technology will allow the generation of entirely novel methods

for screening, treatment and prevention of androgen resistant
prostate cancer.
Contact:
Matt Boehm
mboehm@unmc.edu
402-559-2166
TECHNOLOGY
107
2020
NR-6-R cells
Cell line available for study of FGF activity
Research Tools
Fibroblast Growth
Factors (FGFs) and
fibroblast growth
factor receptors
together form a highly
conserved signaling
system that is used in
both developmental
and physiological
processes of the
adult. The 18 known
FGFs are involved
in the development
and homeostasis of
virtually every human
tissue. Given its
ubiquity, establishing
FGF activity is
a critical step in
understanding a wide
variety of biological
processes.
Scientists at the University of Nebraska Medical Center have

substantial expertise in assaying FGFs. Specifically, the isolation of
NR-6-R cells and their use as a highly sensitive bioassay for FGFs
was first reported by Dr. Angie Rizzino at UNMC within the Eppley
Institute for Research in Cancer and Allied Diseases.
NR-6-R cells are a versatile and sensitive tool for determining FGF
activity and have been employed in a variety of assays. UNeMed
is currently offering licensing
opportunities for the NR-6-R
Rundown cells produced in Dr. Rizzino’s
n Research use only laboratory. The cells can be
n Non-exclusive licenses available employed in a wide variety
of assays, such as soft agar
INVENTOR assays and proliferation
n Angie Rizzino, Ph.D. assays, to identify and
measure FGF activity.
Contact:
Matt Boehm
mboehm@unmc.edu
402-559-2166
108 TECHNOLOGY
2020
ANTIBODIES PORTFOLIO
Anti-Ajuba that join cells to one another.
Ajuba plays an important role in regulation Epitope: N-terminal region of Extracellular
of the kinase activity of AURKA/Aurora-A for domain 1 of desmoglein 2 and a region that is at
mitotic commitment. Ajuba is a component the fusion between EC1 and the proregion
Research Tools
of the IL-1 signaling pathway modulating IL-1- Species: Human
induced NF-κB activation and also plays a role Uses: WB, IF
in cadherin-mediated cell-cell adhesion and Type: Mouse mAb
influences cell migration. Publications: Keim S et al (2008) Hybridoma 27
Epitope: Human Ajuba (4) 249-258
Species: Human
Uses: WB, IF Anti-Desmoglein 2 (10D2)
Type: Mouse mAb Desmogleins are a family of cadherins that
Publications: None play a role in the formation of desmosomes
that join cells to one another.
Anti-ADA3 clone (5C9/C8) Epitope: C-terminal region of extracellular
Epitope: Human ADA3 domain 1 of desomglein 2
Species: Human Species: Human
Uses: WB, IHC Uses: WB, IP, IF
Type: Mouse mAb Type: Mouse mAb
Publications: Mohibi S et al. J. Biol Chem (2012) Publications: Keim S et al (2008) Hybridoma 27
v287: 29442-29456 ; Mirza et al. Breast Cancer Res (4) 249-258
Treat (2013) v137: 721-731; Mohibi S et al. J. Biol
Chem (2015) V290: 28299-28310 Anti-Desmoglein 2 (13B11)
Desmogleins are a family of cadherins that
Anti-Cadherin 11 (16A6) play a role in the formation of desmosomes
Cadherins are integral membrane proteins that join cells to one another.
that mediate calcium-dependent cell-cell Epitope: C-terminal region of extracellular
adhesion. domain 1 of desomglein 2
Epitope: EC domain Cad11 Species: Human
Species: Human Uses: WB, IP
Uses: WB,IP, IF Type: Mouse mAb
Type: Mouse mAb Publications: Keim S et al (2008) Hybridoma 27
Publications: None (4) 249-258
Anti-Cadherin 11 (16G5) Anti-Desmoglein 2 (19B9)

Cadherins are integral membrane proteins Desmogleins are a family of cadherins that
that mediate calcium-dependent cell-cell play a role in the formation of desmosomes
adhesion. that join cells to one another.
Epitope: EC domain Cad11 Epitope: N-terminal region of Extracellular
Species: Human domain 1 of desmoglein 2 and a region that is at
Uses: WB, IP, IF the fusion between EC1 and the proregion
Type: Mouse mAb Species: Human
Publications: None Uses: WB, IF
Type: Mouse mAb
Anti-Cadherin 19 (1C11) Publications: Keim S et al (2008) Hybridoma 27
Cadherins are integral membrane proteins (4) 249-258
that mediate calcium-dependent cell-cell
adhesion. Anti-DHHC5 (11G11)
Epitope: Human Cadeherin 19 DHHC5 is a member of the DHHC family of
Species: Human palmitoyl-cyl transferases. These enzymes
Uses: WB catalyze the addition of palmitate onto
Type: Mouse mAb cysteine residues of target proteins.
Publications: None Epitope: Human DHHC5
Species: Human
Anti-Desmoglein 2 (7H9) Uses: WB
Desmogleins are a family of cadherins that Type: Mouse mAb
play a role in the formation of desmosomes Publications: None
WB—Western Blot IF—Immunofluorescence IP—Immunoprecipitation IHC—Immunohistochemistry
Contact:
Matt Boehm
mboehm@unmc.edu
402-559-2166
TECHNOLOGY
109
2020
PORTFOLIO ANTIBODIES
Anti-DHHC13 (26D1) Anti-MUC4 (8G7)
DHHC13 is a member of the DHHC family Mucin-4 (MUC4) is a mucin protein and a
of palmitoyl-cyl transferases. These enzymes major constituent of mucus. MUC4 plays
catalyze the addition of palmitate onto various roles in the progression of cancer,
Research Tools
cysteine residues of target proteins. particularly due to its signaling and anti-
Epitope: Amino acids 40-150 adhesive properties which contribute to
Species: Human tumor development and metastasis. MUC4
Uses: WB, IF is also important in other diseases such
Type: Mouse mAb as endometriosis and inflammatory bowel
Publications: None disease.
Epitope: Tadem Repeat Domains
Anti-FGFR4 (19H3) Species: Human
Fibroblast growth factor receptor 4 (FGFR4), Uses: WB, IF, IHC
also known as CD334, is a member of the Type: mAb
fibroblast growth factor receptor family and Publications: Moniaux N et al (2004) J Histochem
a cell surface tyrosine kinase containing Cytochem 52 (2) 253-261
three immunoglobulin-like domains. FGFR4
is widely expressed in many tissues including Anti-NHERF-2 (32B6)
the intestine, muscle, heart, cornea, retina, and Sodium-hydrogen exchange regulatory
pancreas, with highest expression in lung and cofactor NHE-RF2 (NHERF-2) is also known
kidney. FGFR4 binds acidic fibroblast growth as tyrosine kinase activator protein 1 (TKA-1)
factor and ligand binding induces mitogenesis or SRY-interacting protein 1 (SIP-1). NHERF-2
and differentiation. FGFR4 is overexpressed in acts as a scaffold protein connecting plasma
gynecological tumor samples, suggesting a membrane proteins with members of the
role in breast and ovarian tumorigenesis. ezrin/moesin/radixin family, linking them to
Epitope: Human FGFR4 the actin cytoskeleton and regulating their
Species: Human surface expression.
Uses: WB, IP, IF Epitope: AA 149-231
Publications: None Uses: WB, IP, IF
Type: Mouse mAb
Anti-LGR6 (20E3) Publications: Theisen C et al (2007) Mol Biol Cell
LGR6 is a glycoprotein hormone receptor 18 (4) 1220-1232
that is a member of the leucine-rich repeat-
containing subgroup of the G protein-coupled Anti-OTK18
7-transmembrane protein superfamily. OTK18 is classified as a transcription
Epitope: Human LGR6 factor as it contains 13 C2H2-type DNA
Species: Human binding zinc finger motifs. C2H2 zinc finger
Uses: WB motifs are capable of binding to a wide
Type: Mouse mAb range of DNA sequences, including the HIV-
Publications: None 1 LTR. This human immunodeficiency virus
(HIV)-inducible zinc-finger protein reduces
Anti-MastL progeny-virion production in infected human
Microtubule-associated serine/thre- macrophages.
onine-protein kinase-like (MastL) has been as- Epitope: OTK 1-178
sociated with thrombocytopenia and throm- Species: Human
bocytopenia 2. MastL is a serine/threonine Uses: ELISA, WB, IHC
kinase that plays a key role in M phase by act- Type: mAb
ing as a regulator of mitosis entry and mmain- Publications: Buescher J et al (2008) J
tenance. Following DNA damage, MastL is Neuroimmune Pharmacol 3 (4) 230-235
also involved in checkpoint recovery by being
inhibited. May be involved in megakaryocyte
differentiation.
Epitope: C-terminus
Species: Human
Uses: WB, IHC
Type: Mouse mAb
Publications: None
Contact:
Matt Boehm
mboehm@unmc.edu
402-559-2166
110 TECHNOLOGY
2020
ANTIBODIES PORTFOLIO
Anti-p63 (11H1) Anti-Pro Desmoplakin (20B6)

A member of the p53 familyof transcription Desmoplakin is a component of
factors, p63 plays a key role in the regulation desmosomes, the intercellular junctions
of epithelial proliferation and differentiation. that tightly link adjacent cells. Desmoplakins
Research Tools
Epitope: Human p63 anchor intermediate filaments to desmosomal
Species: Human plaques.
Uses: WB Epitope: 20B6
Publications: None Uses: WB, IP, IF
Type: Mouse mAb
Anti-Plakophilin-1 (19F10) Publications: Sobolik-Delmaire T et al (2006) JBC
Plakophilins are proteins of the cytoskeleton. 281 (25) 16962-16970
Epitope: AA 235-726
Species: Human Anti-Pro Desmoplakin (23F4)
Uses: WB, IP, IF Desmoplakin is a component of
Type: Mouse mAb desmosomes, the intercellular junctions
Publications: Sobolik-Delmaire T et al (2010) J that tightly link adjacent cells. Desmoplakins
Invest Dermatol 130 911): 2638-46 anchor intermediate filaments to desmosomal
plaques.
Anti-Plakophilin-2 (8H6) Epitope: 23F4
Plakophilins are proteins of the cytoskeleton. Species: Human
Epitope: AA 1-350 Uses: WB, IP, IF
Species: Human Type: Mouse mAb
Uses: WB, IP, IF Publications: Stojadinovic O et al (2008) J Cell Mol
Type: Mouse mAb Med 12 (6B) 2675-2690
Publications: Sobolik-Delmaire T et al (2010) J
Invest Dermatol 130 911): 2638-46 Anti-α-Catulin (22B9)
α-catulin is an α-catenin-related protein that
Anti-Plakophilin-3 (7F6) shares structural similarities with cytoskeletal
Plakophilins are proteins of the cytoskeleton. linker proteins and facilitates Rho signalling.
Epitope: AA 1-308 Eptitope: Human α-catulin
Species: Human Species: Human
Uses: WB, IP, IF Uses: WB
Type: Mouse mAb Type: Mouse mAb
Publications: None Publications: None
Anti-Pro Desmoglein 2 (3B11) Anti Tau-Tubulin Kinase 1

Desmogleins are a family of cadherins that Epitope: Catalytic domain (1-320)
play a role in the formation of desmosomes Species: Human
that join cells to one another. Uses: WB, IHC
Epitope: Proregion human desmoglein 2 Type: Mouse mAb
Species: Human Publications: Sato S et al. J Neurosci (2008) v28:
Uses: WB, IF 14511-14521 ; Xu J et al. FASEBJ (2010) v24:
Type: Mouse mAb 2904-2915; Asai H et al. Am J Pathol (2014) v184:
Publications: Keim S et al (2008) Hybridoma 27 808-818
(4) 249-258
Anti-Pro Desmoglein 2 (20G1)

Desmogleins are a family of cadherins that
play a role in the formation of desmosomes
that join cells to one another.
Epitope: Proregion human desmoglein 2
Species: Human
Uses: WB, IF
Type: Mouse mAb
Publications: Keim S et al (2008) Hybridoma 27
(4) 249-258
Contact:
Matt Boehm
mboehm@unmc.edu
402-559-2166
TECHNOLOGY
2020
cancer PORTFOLIO
cardiovascular
drug delivery
infectious diseases
medical devices
metabolic
miscellaneous
neurologic
research tools
software
startups
112 TECHNOLOGY
2020
SOFTWARE PORTFOLIO
COVID-19
Modular Electronic Decision Support Builder
Pediatric interactive screening
tool adapts to institutional needs
Physicians from Omaha’s institutional-level branding and
Children’s Hospital and Medical adjustment of content to fit the
Center have developed a local context.
pediatric-specific COVID-19
Software
screener. This application can Commercial applications

be accessed by a one-time include user data analytics
download as an offline app or and observation, branding and
directly on the web. delivery of content to target
populations, use in public
This tool can be used by a health, and dissemination or
variety of clinical and non- implementation of projects to
clinical end-users to access improve healthcare processes
information step-by-step. The or outcomes. The combination
software also provides tracking of customizable content, user
to connect user behavior with analytics, and interactive
access of tagged content within surveys combines multiple
the tool. The customization distinct features into a single
nature of the tool allows for software tool.
Rundown
n COVID-19 screener specifically
for pediatric patients
n Available as a web-based or
native app
n Allows for institutional-level
branding
INVENTORS
n Ellen Kerns
n Russell McCulloh
Contact:
402-559-3265
TECHNOLOGY
113
2020
PORTFOLIO SOFTWARE
COVID-19
COVID-19 Screener
Rapidly screen patients for COVID-19
Clinicians at the University of for other disease states. For
Nebraska Medical Center’s example, this tool could help
Department of Emergency a patient decide if they have a
Medicine have developed a simple case of a sore throat or
patient-focused screening a case of streptococcus. The
platform that allows patients screener then suggests if the
Software
to engage with a screening patient should see a doctor
algorithm that can calculate the or reach for over-the-counter
patient’s risk and probability care based on the severity of
of a COVID-19 diagnosis. This symptoms. This screener, by
technology also provides the steering consumer’s decision
patient with recommendations making process, has the ability
that are specific to their unique to work with local pharmacies
scenario and set of symptoms. and increase foot traffic.
The advantage of this

technology over similar
technologies is that the
clinicians have incorporated Rundown
design logic based on current n Quick assessment based on
medical emergencies that are symptoms
associated with the disease of n Differentiates between emer-
interest. The screening logic is gent, non-emergent scenarios
able to decipher and weed out n Inform, manage patient deci-
emergent cases while providing sion-making
next-step resources to the n Can be modified to fit any
disease state
patient. This patient-consumer
health informatics platform INVENTORS
allows for the development and n Michael Wadman
implementation of consumer n Thang Nguyen
focused technology that n Wesley Zeger
promotes well-being and
optimal health.
The screening tool can be used
Contact:
402-559-3265
114 TECHNOLOGY
2020
SOFTWARE PORTFOLIO
Motion capture system

Use a smartphone for
true motion capture system
Motion capture is a
growing and versatile
tool. From 3D animation
to physical therapy,
Software
the data from motion

capture is gaining
wider and wider usage.
Unfortunately, motion
capture requires
multiple high-speed
cameras and a variety
of active or passive
reflectors. Expensive and
complicated equipment
limits wider use.
Mobile motion capture technologies exist but lack versatility.

Current systems only record video, which must be processed at
a later date. Even then, the information from the motion capture
systems is not always at the same level of quality, which limits the
utility of the motion capture data.
Doctors Ka-Chun Siu and JC Chien invented new algorithm

that allows for true mobile motion capture using a smartphone.
Unlike other mobile motion capture systems, their invention
makes it possible for real time motion capture, without expensive
equipment—just a camera and some disposable markers. In
laboratory tests, the mobile motion capture system captured
motion just as precisely as a state of the art motion capture
laboratory system.
Contact:
Joe Runge
hrunge@unmc.edu
402-559-1181
TECHNOLOGY
115
2020
PORTFOLIO SOFTWARE
Patient management, charting
Software improves CPR, keeps
complete record during codes
UNMC’s newest patient management application streamlines medical
complexity and simplifies decision support into a simple blueprint
that standardizes care for all patients regardless of circumstance,
stress, training and experience.
Software
It’s rare when a patient’s heart
stops or codes, but when they Rundown
do doctors and nurses must have n Get it right all the time
current guidelines at the ready. It’s a n Standardize care every-
complex, high-stress scenario where where
any number of things can go wrong. n Eliminates need to recall
A seemingly simple error can be the forgotten protocols
difference between life and death. n Easy and dynamic charting
real-time
Emergency medicine physician n Keep track of medications
Michael Wadman and nurse and doses
practitioner Thang Nguyen joined n Review past interventions
forces to create a catch-all solution:
A web-based application that helps INVENTORS
physicians and nurses in real-time n Michael Wadman, M.D.
analyze patients, obtain guidelines, n Thang Nguyen, A.P.R.N.
and document the course of care. n Trong Nguyen
The patient management software helps physicians and nurses get

it right all the time. It mitigates the potential for error. As a clinically-
driven decision support system, it analyzes the patient’s status based
on user input and offers clinically-based recommendations.
At the same time, it raises the standard of care, creating better

outcomes, better doctors, better nurses and happier patients.
With this system at their side, doctors can fully focus on improving
the survival and outcome of code patients.
Because the web-based application automatically cues providers,

it can be easily modified to include guidelines for other medical
emergencies, such as stroke or poisoning. The application could also
function as a training tool for the next generation of clinicians.
Contact:
402-559-3265

116 TECHNOLOGY
2020
SOFTWARE PORTFOLIO
Cancer classification algorithm

Identify critical cancer
biomarkers with a single sample
A new and powerful algorithm could help
in the diagnosis and prognosis of any Powerful prognosis,
cancer.
diagnosis tool
The discovery of cancer-specific gene n Reference based meth-
Software
od for gene biomarker

biomarkers can significantly improve
discovery
diagnosis and enable personalized n Classify cancer type
therapy. Unlike current cancer screening using gene expression
strategies that are largely based on data
imaging techniques, this algorithm n Diagnosis, prognosis
represents a purely data-driven method from a single clinical
to identify biomarkers. sample
n Novel algorithm re-
Unlike other gene discovery algorithms quires no prior knowl-
under development, this technology edge to use
requires relatively less processing
INVENTORS
power, yet provides true single-sample n Amar Singh, Ph.D.
diagnostic potential. Plus, the novel n Dhundy Bastola, Ph.D.
software is easy to use, and does not n Ling Zhang, Ph.D.
require medical knowledge for the user.
As a proof-of-concept, the inventors have used the algorithm to

positively identify specific biomarkers in colorectal, stomach and lung
cancer samples. However, the algorithm could be further trained to
theoretically identify biomarkers for many different diseases.
Contact:
Tyler Scherr
402-559-2140

TECHNOLOGY
117
2020
PORTFOLIO SOFTWARE
Fall risk assessment insole
Predict fall risk to prevent injuries
Slips and falls are random.
But we know several Rundown
risk factors that make n One-third of adults older than 65 fall
falling down much more each year
likely. Risk factors include n Two-thirds of adults older than 65
advancing age, visual have been hospitalized after a fall
impairments, muscle n Portable insole assesses risk of
Software
weakness and even prior falling in minutes
n Fall risk can be assessed with 90
hospitalization.
percent specificity
A special insole and a INVENTOR
proprietary algorithm could n Arash Gonabadi, Ph.D.
help physicians more n Max Kurz, Ph.D.
accurately predict the n Nicholas Stergiou, Ph.D.
likelihood of falling, and n Philippe Malcolm, Ph.D.
help prevent serious injuries
to elderly patients in particular.
Nick Stergiou, Ph.D., and his colleagues in the biomechanics

department at the University of Nebraska at Omaha, developed
such a device—the insole and the accompanying algorithm—for
fall-risk assessment. The portable, wireless device can be easily
worn to collect critical biometric data after a few minutes of
walking. The data can
be stored on the device
and transferred to the
program via USB, or
uploaded wirelessly to
the cloud.
The current prototype

assesses fall risk in a
small population with
90 percent specificity.
The research team
believes they can
refine the algorithm
to increase specificity
even further with a
larger sample size.
Contact:
Tyler Scherr
402-559-2140

118 TECHNOLOGY
2020
SOFTWARE PORTFOLIO
UNePlan Strategic Planning

Tracking big goals doesn’t
have to be a big problem
Professionals at the University of Nebraska developed a solution
to the often overly complicated and limited options in strategic
planning software for major institutions.
As the state’s largest employer, the University of Nebraska required

Software
a complex solution to manage wide-ranging goals and objective.

Like any massive organization,
Nebraska’s strategic plan
spans a wide array of interests Rundown
and objectives—including four n Track long-term goal progres-
campuses; the state’s largest sion over time, even years
teaching hospital; and enough n Monitor individual goals in
departments, colleges and units real-time, not just big picture
checklists
to staff 16,000 people, and teach n Filter and sorting options
more than 55,000 students in all allow deeper understanding of
93 counties. successes and shortfalls
n Highly efficient, customizable
Nebraska’s novel solution to platform can fit most institu-
managing such complexity tion’s needs
is called UNePlan Strategic
Planning. It’s a dynamic software INVENTORS
platform far more flexible and n Jeffrey Gold, M.D.
efficient than current options n David Padgett
available on the market.
UNePlan allows institutions to set, manage and monitor their

objectives however they wish. For example, a large university might
use an organizational structure, customizing their strategic plan
according to each campus’ particular strengths. Individual campus
goals could then be filtered by the departments in each unit.
Another institution, however, might prefer a more function-oriented
structure or a relational structure that could organize strategic goals
by leadership teams and management groups.
The high-level of customization—and the ability to tag individuals

at every level in the planning process—makes UNePlan an ideal
option for large-scale strategic planning.
Contact:
Steve Schreiner
sjschreiner@unmc.edu
402-559-2176
TECHNOLOGY
119
2020
PORTFOLIO SOFTWARE
Smartphone app uses

biomechanics to help elderly
Something as simple as walking to the beat of chaotic music can
help prevent falls in the elderly.
New research from the University of Nebraska at Omaha

demonstrates that elderly gait can be made more stable by
Software
listening to music with a variable beat: chaotic music.
By simply walking in-beat with chaotic music, gait stability

dramatically improved in the elderly, which, in turn, improves safety
and fall prevention.
The research is based on the work of UNO’s world-leading expert

on biomechanics, Nicholas Stergiou, Ph.D. Biomechanics, the
study of human movement, demonstrates that a lot can be learned
about a person from the variability of their movements.
A person with Parkinson’s disease has too much variability. A

person with an orthopedic injury has much, much less.
The key to healthy movement is finding and maintaining the right

balance of variability in movement.
Contact:
Joe Runge
hrunge@unmc.edu
402-559-1181
120 TECHNOLOGY
2020
SOFTWARE PORTFOLIO
Laparoscopic simulator
Affordable simulator helps train doctors faster
Surgical training is facing a crisis. Restrictions on resident work
hours have put new pressures on surgical residency: how do you
train new surgeons on fewer residency hours?
The problem is especially acute for laparoscopic surgery. Minimally

invasive surgery requires very particular skills that take a long time
to master.
Software
One solution is laparoscopic

simulation. Medical simulation Rundown
offers a solution to make the most n Sofware as a Service
of the time available to surgical n Internet-based software
trainees. Medical simulations must makes computer-assisted
be innovative. To maximize their simulation affordable for all
value, simulators must be readily trainees
accessible and provide simulations n Integrated tracking of utiliza-
that help trainees acquire skills tion, progress
rapidly. n Objective, evidence-based,
FLS-ready determination of
Current simulators require competency
residency programs to choose:
inexpensive simulators with INVENTORS
unsophisticated simulations or n Dimitry Oleynikov, M.D.
complex, expensive simulators n Joseph Siu, Ph.D.
that provide richer simulation n Carl Nelson, Ph.D.
environments.
A team of surgeons and scientists at the University of Nebraska

Medical Center invented a new simulator platform that will
revolutionize laparoscopic simulation. The simulator itself is
inexpensive to produce with the potential for each trainee to get
her own simulator. The simulator interfaces with any personal
computer. It connects over the internet to an online simulator
service that simulates tasks that teach the fundamentals
of laparoscopic surgery. The system captures the trainee’s
performance, offers realtime feedback and evaluation and provides
the residency director evaluations of each trainee.
The simulator creates a new software as a service (SAAS) business

model for medical simulation. In addition it allows the latest
approaches used in popular video games to create more engaging
simulation environments.
By creating simulation environments that feel more like medical

simulation games the new simulation platform provides new
opportunities for custom simulation services to surgical residency
programs.
Contact:
Joe Runge
hrunge@unmc.edu
402-559-1181
TECHNOLOGY
2020
cancer PORTFOLIO
cardiovascular
drug delivery
infectious diseases
medical devices
metabolic
miscellaneous
neurologic
research tools
software
startups
122 TECHNOLOGY
2020
STARTUPS PORTFOLIO
A selection of key startups born from UNMC innovations.
AcademicEdgar+
Burch Kealey, Ph.D., developed and licensed software to make EDGAR searches more efficient. Dr.
Kealey, an accounting associate professor of at the University of Nebraska at Omaha, developed the
program as a way to solve frustrations he encountered during a large research project.
Actorius Pharmaceuticals, Inc.

Formed around an siRNA delivery system developed in the lab of Joe Vetro, Ph.D. The siRNA
delivery system helps protect the siRNA from degradation and can be used to improve systemic
administration of siRNA-based therapies. Actorius Pharmaceuticals is currently developing the
siRNA delivery technology to treat various forms of cancer including breast cancer.
Avert
Startups
An early product of the Omaha startup scene and the Biomechanics Department at the University
of Nebraska Omaha, Avert is building a non-invasive concussion detection system combining
biomechanics, artificial intelligence and cloud computing. The result is highly accurate, low-cost
device that can reliably determine when a person receives a concussion and when they recover.
BehaviorApp, LLC
UNMC psychology and pediatrics professor Keith Allen, Ph.D., partnered with Lincoln-based app
developer, SectorNow, on an application that helps parents communicate with autistic children.
Based on Dr. Allen’s research and naturalistic teaching method, the app was pushed through
development through his startup company, BehaviorApp. Called MySocius, the app is available
through the iTunes App Store.
Breezmed
Breezmed is a health informatics startup developing a new platform to ease workflow around
prior authorizations. Breezmed streamlines the different documents insurance companies often
require, making it easier for patients to get their prescriptions.
Calidum, Inc.
Calidum Inc, was formed around an innovative approach for simultaneously treating and
diagnosing some of the deadliest cancers. Janina Baranowska-Kortylewicz, Ph.D., a professor and
radiochemist at UNMC, developed “theranostic” compounds tagged with a radioactive isotope that
will help clinicians better diagnose, track and treat various cancers that include prostate, ovarian,
and triple negative breast cancer. The compounds could also be used on two rare forms of brain
tumors, neuroblastoma and glioblastoma.
Camras Vision, Inc.

Camras Vision was founded on an intraocular pressure device developed by the late Carl Camras,
M.D., a UNMC physician. His daughter, Lucinda, founded the company and is working with an
MBA student from Duke University to develop a business plan. They have won business plan
competitions, and have secured $326,000 in Small Business Innovation Research funding.
Ensign Pharmaceutical, Inc.

Formed around a thermosensitive hydrogel formulation that can be used to deliver a variety
of therapeutics. The thermosensitive hydrogel formulation is a liquid at room temperature and
once injected into the body it forms a hydrogel allowing for better control of drug release from
the formulation. Ensign Pharmaceutical is initially focusing the development of the hydrogel
formulation for the treatment of osteoarthritis.
Global Laparoscopic Solutions

A medical Device company built around the global expertise of Chandrakanth Are, M.D., and
founded by the veteran entrepreneurs of St. Louis’ Exeteur group. GLS is building the portable
laparoscope, a medical device concept that will bring laparoscopic surgery out the minimally
invasive surgical suite and to billions of people currently underserved by surgical technology.
Contact:
Joe Runge
hrunge@unmc.edu
402-559-1181
TECHNOLOGY
123
2020
PORTFOLIO STARTUPS
LabPoint
Originally created as a software company that solely provided services for UNMC and the state
public health lab. LabPoint has since expanded to offer services to the wider marketplace with
further development of their cornerstone product, ELIRT. Aimed at the healthcare industry, ELIRT
is a cloud-based software package that helps streamline the lab ordering process and improves
lab reporting.
Prommune Inc.
Late UNMC researcher Sam Sanderson, Ph.D., founded Prommune to develop his innovation, EP-
67, a protein formulation that can serve as a platform to activate and enhance the natural immune
system for a number of conditions. Prommune is currently focused on using EP-67 to deliver a
more effective vaccine for the H1N1 virus in pigs. In the future, Prommune hopes to expand to other
conditions and perhaps human use.
Startups
ProTransit NanoTherapy
Co-founded by former Entrepreneur-In-Residence, Gary Madsen, Ph.D., ProTransit Nanotherapy
is based on the work of former UNMC researcher Vinod Labshetwar, Ph.D., who is also a co-
founder in the Omaha-based startup. ProTransit is developing a nanoparticle as a delivery vehicle
for antioxidant enzymes to the deepest layers of the skin. The final product could be a topical
application such as skin cream or sun lotion that better protects the skin against cancer, blemishes
and wrinkles. There is also potential for additional applications that include treatment for some
spinal cord injuries or certain types of brain damage.
Radux Devices LCC

Greg Gordon, M.D., a former Interventional Radiologist at UNMC and the Veteran’s Administration,
is commercializing new tools that help reduce radiation exposure. The devices also reduce the
stress and strain often experienced by interventional radiologists, improving their work flow,
efficiency, career longevity and quality of life.
ScanMed of Resonance Innovation Inc.

ScanMed was created in the 1990s when UNMC faculty member Randy Jones, Ph.D.,
commercialized MRI coils he created. ScanMed later escaped the economic downturn by pivoting
into a service company that repairs MRI scanning coils. More recently, ScanMed has enjoyed
significant growth and now uses its repair service to bankroll some of the most innovative MRI
coil designs in the world, including a novel prostate cancer screening coil that could dramatically
improve a physician’s ability to make the earliest possible diagnosis.
Shannon Pharmaceuticals Inc.

Formed to develop a novel glucocorticoid prodrug (ZSJ-0228) developed in the lab by UNMC
researcher, Dong Wang, Ph.D. The novel glucocorticoid prodrug has improved efficacy and reduced
toxicity compared to standard glucocorticoid treatments. Shannon Pharmaceuticals is developing
ZSJ-0228 for the treatment of systemic lupus erythematosus and various kidney diseases.
Vireo Resources
Nebraska manufacturing startup Vireo Systems was established in Plattsmouth, Neb., about 20
miles south of Omaha. Vireo manufactures popular muscle-building health supplements that were
developed at UNMC, Creatine Ethyl Ester and Creatine HCL. Vireo eventually outgrew its first facility,
expanding into a larger space in 2012. More than 20 Nebraskans are employed at Vireo, which holds
more than 40 manufacturing contracts.
Virtual Incision Corporation

Virtual Incision was born out of a collaboration between UNMC surgeon Dmitry Oleynikov and UNL
robotics engineering professor Shane Farritor. Together, the cofounders are developing miniaturized
surgical robots that could transform highly invasive major surgeries into minimally invasive
procedures. Their surgical platform has also shown potential for remote surgical applications, and
has undergone zero-gravity testing with NASA. In 2015, Virtual Incision raised more than $11.2
million, then entered first human trials in 2016, and raised another $13 million for Series B financing
in 2017.
Contact:
Joe Runge
hrunge@unmc.edu
402-559-1181
This page intentionally blank
TECHNOLOGY
2020 PORTFOLIO
402-559-2468
unemed@unmc.edu
http://www.unemed.com
Mail:
986099 Nebraska Medical Center
Location:
4460 Farnam St., Ste. 3000
It is the policy of the University of Nebraska not to discriminate based upon age, race, ethnicity, color, national origin, gender, sex,
pregnancy, disability, sexual orientation, genetic information, veteran’s status, marital status, religion or political affiliation.

UNeMed Technology Portfolio

Încărcat de

Informații document

Drepturi de autor

Formate disponibile

Partajați acest document

Partajați sau inserați document

Opțiuni de partajare

Vi se pare util acest document?

Este necorespunzător acest conținut?

Drepturi de autor:

Formate disponibile

UNeMed Technology Portfolio

Încărcat de

Drepturi de autor:

Formate disponibile

TECHNOLOGY1

Revised: October 1, 2020

As a proof-of-concept, the inventors have used the algorithm to

SMZL specific biomarkers

Splenic marginal zone

of the spleen, affects

UNeMed Corporation is the technology transfer office for the University of

UNMC’s compounds selectively target INVENTORS

UNeMed Corporation is the technology transfer office for the University of

New approach for myeloma, other cancers

The new drugs

UNeMed Corporation is the technology transfer office for the University of

NF-κB Pathway Inhibitor

The NF-κB pathway

Amarnath Natarajan, Ph.D., and his team developed a small molecule

UNeMed Corporation is the technology transfer office for the University of

Target for cancer stem cells

Stem cells—the cell-building dynamos that produce functional

aggressiveness and ability to spread to other organs.

Some types of cancer, such as

Researchers at the University of INVENTOR

PD2 is normally involved in the maintenance of stem cells and

UNMC researchers are currently screening libraries of small

In addition to use as a standalone immunotherapy, the CCL21

By enhancing immune infiltration into tumors, the CCL21

NF-kB Pathway Inhibitors

Every year, roughly 45,000 people

treatment options, almost 43,000

The few treatments that exist are

But researchers at the University of Nebraska Medical Center may

“13-197” is still in preclinical development for pancreatic cancer,

Most cancer treatments

A nanogel developed by former UNMC researcher Alexander

One potentially effective way to treat high blood pressure is to

UNMC’s detection system non-invasively monitors sympathetic

UNMC researchers have shown that the sympathetic vasomotion

The sympathetic vasomotion detection system is a versatile tool

In addition to their work with renal denervation, UNMC researchers

Rapid co-culture model for atherosclerotic diseases

UNeMed Corporation is the technology transfer office for the University of

Together, they have invented a new pediatric medical device to

The improved device has permeable membranes to help the

Doctors Hammel and Delaney are prepared to conduct an animal

To get around this hurdle, Drs.

The CCL21 nanoparticle formulations have been developed, and

In addition to use as a standalone immunotherapy, the CCL21

By enhancing immune infiltration into tumors, the CCL21

Anti-inflammatory polymers for IBD

The new therapy is based on an improved version of chloroquine, a

The digestive system does not actively absorb the chloroquine-

The chloroquine-based polymers can also be used to package and

Antiretroviral therapies, or ART, are also ineffective at reaching viral

LaserART targets the immune system’s hunter cells, or macrophages,

With further development LaserART could have a dramatic impact on

UNeMed Corporation is the technology transfer office for the University of

This new device is a

The nanofiber rings can

The unique properties of the nanofiber ring structure make it ideal

A nanogel developed by former UNMC researcher Alexander

Photo: National Institute of Allergy and Infectious Diseases

LaserART harnesses the power of the patient’s immune system to

LaserART targets the immune system’s hunter cells, or macrophages,

With further development LaserART could have a dramatic impact on

UNeMed Corporation is the technology transfer office for the University of